{"meta":{"query_hash":"5eb94abd487e","filters":{"venue":"Journal of Hematology & Oncology"},"cohort_total":63,"direct_labels_cover":0,"predictions_cover":63,"exported":63,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5eb94abd487e","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Hematology+%26+Oncology"},"results":[{"id":"W2000221743","doi":"10.1186/1756-8722-1-8","title":"Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)","year":2008,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Coleman Foundation","keywords":"Myeloid leukemia; Leukemia; Myeloid; Cancer research; Biology; Phage display; Peptide library; Biopanning; Immunology; Antibody; Biochemistry; Peptide sequence","score_opus":0.028845974154937348,"score_gpt":0.2923246518097474,"score_spread":0.2634786776548101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000221743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682415,0.0007812653,0.00016986653,0.0009696327,0.00014820996,0.00018501026,0.00003171443,0.000005063446,0.0008850948],"genre_scores_gemma":[0.9875724,0.0031892825,0.008717223,0.0002107617,0.000110117275,0.0000022120657,0.000022223609,0.0000112204925,0.00016461013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985702,0.00016448527,0.0005213807,0.00019674473,0.00028881055,0.00025836003],"domain_scores_gemma":[0.99790925,0.000779679,0.0006258151,0.000116127834,0.0003958531,0.00017328364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015478527,0.00016732341,0.0009467542,0.0002107962,0.00008890879,0.0000032252624,0.00012486511,0.00026250893,0.00019164184],"category_scores_gemma":[0.00005050904,0.000100238736,0.00011599713,0.0001096607,0.00070323504,0.000103915176,0.000069031434,0.0004951008,0.000012717093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017807938,0.0006873457,0.84107727,0.000051927138,0.0010863229,0.0025337022,0.0009991328,0.0000042521506,0.12751107,0.0001975862,0.003076092,0.0049673463],"study_design_scores_gemma":[0.0057364455,0.009953889,0.8956488,0.00013558629,0.00021378038,0.006323696,0.00032715837,0.000014117648,0.072499834,0.0003591397,0.008621489,0.00016608772],"about_ca_topic_score_codex":0.00004419513,"about_ca_topic_score_gemma":0.000020243579,"teacher_disagreement_score":0.055011228,"about_ca_system_score_codex":0.00012558005,"about_ca_system_score_gemma":0.00045081862,"threshold_uncertainty_score":0.4087617},"labels":[],"label_agreement":null},{"id":"W2098128741","doi":"10.1186/1756-8722-7-21","title":"Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis","year":2014,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Prostate Cancer Canada; University of Calgary","funders":"Prostate Cancer Canada; Movember Foundation; Prostate Cancer Foundation","keywords":"PTEN; Prostate cancer; Erg; Immunohistochemistry; Internal medicine; Biochemical recurrence; Medicine; Cohort; Prostate; Cancer; Oncology; Cancer research; Pathology; Biology; Prostatectomy; Signal transduction; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.011443042562657504,"score_gpt":0.3113333247399142,"score_spread":0.2998902821772567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098128741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896034,0.0019006575,0.00012843467,0.0069169435,0.000052377447,0.0010841902,0.0000071777963,0.000008724943,0.00029807934],"genre_scores_gemma":[0.99673635,0.00020722684,0.0024266143,0.00026010317,0.000041816944,0.0001922279,0.000008698327,0.000022746444,0.00010420622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985812,0.00015758652,0.00051022077,0.00020713104,0.00025355525,0.000290318],"domain_scores_gemma":[0.998113,0.000082810315,0.00052347424,0.00015863014,0.00090596563,0.00021615082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034276507,0.00015209579,0.00073707785,0.0002720599,0.000042231688,0.000004803653,0.00009445965,0.00014550709,0.00002167927],"category_scores_gemma":[0.00014896682,0.00009799818,0.000056621397,0.00023893503,0.00017747648,0.000059999806,0.00005051344,0.00025687148,0.000003206347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007146628,0.0008486258,0.9141566,0.00059090497,0.00055424497,0.00023191451,0.0008423113,0.000008157467,0.061783426,0.00069975614,0.0009160868,0.012221299],"study_design_scores_gemma":[0.03335029,0.06606108,0.4641423,0.0017106769,0.001434716,0.0038764223,0.00044578302,0.00009084153,0.4052482,0.00095807604,0.02211319,0.0005684435],"about_ca_topic_score_codex":0.000060275168,"about_ca_topic_score_gemma":0.000057280053,"teacher_disagreement_score":0.45001435,"about_ca_system_score_codex":0.00017054475,"about_ca_system_score_gemma":0.0005208181,"threshold_uncertainty_score":0.39962497},"labels":[],"label_agreement":null},{"id":"W2104096033","doi":"10.1186/1756-8722-3-13","title":"Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma","year":2010,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Mass spectrometry; Hematology; Malignancy; Computational biology; Proteomics; Biomarker discovery; Disease; Internal medicine; Oncology; Bioinformatics; Cancer research; Biology; Chemistry; Biochemistry; Chromatography; Gene","score_opus":0.06230023267059034,"score_gpt":0.4045304902953145,"score_spread":0.3422302576247242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104096033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012028721,0.97652066,0.01283626,0.0029986678,0.0007125719,0.005061888,0.000026664513,0.000036020952,0.00060438924],"genre_scores_gemma":[0.010511736,0.8753086,0.11241056,0.00022916384,0.00035895733,0.0009184833,0.000018751827,0.00013987583,0.00010391308],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605066,0.000448985,0.0018092386,0.00042182798,0.00049335853,0.0007759635],"domain_scores_gemma":[0.9942344,0.0021262225,0.002221215,0.0007344925,0.00034352462,0.00034014625],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011452392,0.00050599466,0.0046804864,0.0023043,0.00015862625,0.000010848707,0.00076106994,0.0012510453,0.000118033444],"category_scores_gemma":[0.0023125901,0.00030204386,0.00082893413,0.0011537474,0.0006019435,0.000057659166,0.0001584926,0.00289581,0.000047497753],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00212995,0.0014884165,0.006181403,0.015788328,0.0034027498,0.00898676,0.00008700933,0.0000054207344,0.0054523395,0.004169489,0.0008352033,0.95147294],"study_design_scores_gemma":[0.00556543,0.005284044,0.000069562906,0.009097787,0.0020350558,0.030210266,0.0003326689,0.00003459301,0.0020547733,0.0010199511,0.94393295,0.0003628912],"about_ca_topic_score_codex":0.0000042180486,"about_ca_topic_score_gemma":0.000025646532,"teacher_disagreement_score":0.95111006,"about_ca_system_score_codex":0.0012348416,"about_ca_system_score_gemma":0.002634236,"threshold_uncertainty_score":0.9999432},"labels":[],"label_agreement":null},{"id":"W2112825380","doi":"10.1186/1756-8722-6-26","title":"Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital Maisonneuve-Rosemont; Université de Sherbrooke","funders":"Cancer Research Society","keywords":"Telomere; Myeloid leukemia; Hematology; Leukemia; Medicine; Biology; Cancer research; Internal medicine; Genetics; DNA","score_opus":0.01536367648813868,"score_gpt":0.2740955660179467,"score_spread":0.258731889529808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112825380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911062,0.0063475086,0.00009188248,0.00029827227,0.000494125,0.00057589635,0.000012825527,0.00001593405,0.0010573418],"genre_scores_gemma":[0.99610734,0.0016573078,0.0018084547,0.00011539127,0.00012869183,0.000016736596,0.000007758076,0.00004469548,0.00011362248],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994637,0.00063349947,0.0029534074,0.0004171747,0.00069913827,0.0006597632],"domain_scores_gemma":[0.9925935,0.0016207778,0.0039131097,0.00051545765,0.0011251955,0.0002319535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001193023,0.00038488835,0.0030630978,0.00095745036,0.00004696079,0.000005421554,0.0006118316,0.00064878404,0.00031473074],"category_scores_gemma":[0.0011062281,0.00033260632,0.00043180902,0.0006527038,0.0009820403,0.00035240076,0.00016017395,0.0011646316,0.000010764112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068688096,0.0011844364,0.079584256,0.0014327818,0.0008547423,0.0014001637,0.0026794996,0.00047538712,0.9004436,0.0002989624,0.0007756346,0.010183628],"study_design_scores_gemma":[0.010280006,0.006684286,0.2305854,0.0030845343,0.0005451653,0.005548815,0.0021040374,0.0009396236,0.7381284,0.0010329067,0.00055474875,0.0005120518],"about_ca_topic_score_codex":0.00050712604,"about_ca_topic_score_gemma":0.000075206946,"teacher_disagreement_score":0.1623152,"about_ca_system_score_codex":0.002010448,"about_ca_system_score_gemma":0.003636455,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2123870670","doi":"10.1186/1756-8722-6-84","title":"Enhancing bone marrow regeneration by SALL4 protein","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; New York State Stem Cell Science","keywords":"Haematopoiesis; Stem cell; Cord blood; Bone marrow; Transplantation; Progenitor cell; Immunology; Cancer research; Biology; Hematology; Regeneration (biology); Medicine; Internal medicine; Cell biology","score_opus":0.004374882000059221,"score_gpt":0.24074081394738667,"score_spread":0.23636593194732744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123870670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838726,0.0067356396,0.0021706922,0.0052659665,0.00045931968,0.0002047361,0.0000013925828,0.0000056408603,0.0012840484],"genre_scores_gemma":[0.9935658,0.0005804657,0.0026639749,0.00085631374,0.00034338122,0.000028742099,0.000016017935,0.000019540512,0.0019257376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870497,0.00017135506,0.00057840574,0.00017548936,0.00011193749,0.00025783674],"domain_scores_gemma":[0.9989445,0.000021089007,0.00053612917,0.0001424973,0.00023845928,0.00011727995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028499708,0.00013710652,0.00038041855,0.00007293598,0.000065433844,0.000011833862,0.0001614497,0.00046753313,0.00011593571],"category_scores_gemma":[0.00010084955,0.000105383115,0.00013455709,0.00006533625,0.00011717979,0.000011442713,0.000043340024,0.0002866639,0.000040735238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009392577,0.0000738561,0.0001459143,0.000016518417,0.00010840926,0.00004433044,0.000028167664,0.000021951877,0.94150895,0.00014818738,0.055284694,0.002525097],"study_design_scores_gemma":[0.0008680163,0.0013996712,0.000041258452,0.00003402698,0.00003144854,0.0028678803,0.00008044232,0.000012539289,0.9046501,0.00036740777,0.08952217,0.00012506622],"about_ca_topic_score_codex":0.000018017388,"about_ca_topic_score_gemma":0.0000283495,"teacher_disagreement_score":0.036858875,"about_ca_system_score_codex":0.000057560126,"about_ca_system_score_gemma":0.00026794302,"threshold_uncertainty_score":0.42973986},"labels":[],"label_agreement":null},{"id":"W2133654917","doi":"10.1186/1756-8722-6-46","title":"A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Sorafenib; Rash; Diffuse large B-cell lymphoma; Hematology; Lymphoma; Oncology; Progression-free survival; Neutropenia; Overall survival; Gastroenterology; Chemotherapy; Hepatocellular carcinoma","score_opus":0.028262361654969093,"score_gpt":0.35753368450433876,"score_spread":0.32927132284936966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133654917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937851,0.0011340032,0.000019175119,0.00093821663,0.00073691475,0.0026508362,0.0000086220425,0.000019064379,0.00070806],"genre_scores_gemma":[0.9985264,0.0001498512,0.0003644864,0.00035666642,0.0001475147,0.00031951984,0.000011029834,0.00004117775,0.00008334717],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9942902,0.0016768365,0.002265452,0.00055194285,0.00051171565,0.00070388615],"domain_scores_gemma":[0.995889,0.00066827977,0.0015942603,0.0005185479,0.0008716604,0.00045822334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012032755,0.00047838347,0.0030361214,0.00073044794,0.00015462845,0.000015501279,0.0003732643,0.0004279757,0.00027167305],"category_scores_gemma":[0.0002151616,0.00034548985,0.00024617102,0.00038332705,0.00020227132,0.00029317537,0.00025522723,0.00049119326,0.0000516801],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041500195,0.66074115,0.28246543,0.000047300207,0.0008495133,0.007352568,0.020575494,0.0000026062887,0.00073050236,0.00011270604,0.0009908584,0.021981884],"study_design_scores_gemma":[0.3637734,0.48692653,0.077981114,0.00013130959,0.0013530809,0.0050696996,0.059641898,0.0001977814,0.00092451024,0.000088688066,0.003556651,0.00035532293],"about_ca_topic_score_codex":0.00037595525,"about_ca_topic_score_gemma":0.004004176,"teacher_disagreement_score":0.3596234,"about_ca_system_score_codex":0.001206622,"about_ca_system_score_gemma":0.0013287166,"threshold_uncertainty_score":0.9998997},"labels":[],"label_agreement":null},{"id":"W2137990944","doi":"10.1186/1756-8722-3-8","title":"From basic research to clinical development of MEK1/2 inhibitors for cancer therapy","year":2010,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":244,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Cancer research; Regulator; Cancer; Kinase; Receptor tyrosine kinase; MAPK/ERK pathway; Hematology; Tyrosine kinase; Signal transduction; Function (biology); Hyperactivation; Medicine; Biology; Internal medicine; Cell biology; Gene; Biochemistry","score_opus":0.23335411210150298,"score_gpt":0.5308665528212848,"score_spread":0.29751244071978183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137990944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02971811,0.96507275,0.00028255503,0.00029555013,0.0035676046,0.00083926413,0.00007166103,0.0000028217835,0.00014969878],"genre_scores_gemma":[0.00023491666,0.9828714,0.013211017,0.00015919586,0.0030196249,0.000205882,0.00007640992,0.000060489267,0.0001610545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99549204,0.0008636026,0.0024367473,0.00047909145,0.00025679026,0.0004717121],"domain_scores_gemma":[0.9958784,0.00094725087,0.0016268126,0.00043382216,0.0008407733,0.00027295627],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033726399,0.0003296162,0.0029281015,0.00033987444,0.00009118459,0.000007916285,0.00079816795,0.0019725435,0.000069397865],"category_scores_gemma":[0.0008034293,0.00024091764,0.00080231234,0.00015571382,0.0002611871,0.0000033685978,0.00023772172,0.0011237832,0.00001461433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037981314,0.0003502489,0.00010904505,0.0006378561,0.00072194834,0.000041662926,0.00013657798,1.1941992e-7,0.0029991467,0.00007270773,0.02677259,0.96777827],"study_design_scores_gemma":[0.000922996,0.0024154065,0.000011972155,0.00096346816,0.00016722476,0.00029467413,0.00004894797,8.8597574e-8,0.009611187,0.00009695093,0.9852634,0.0002036797],"about_ca_topic_score_codex":0.000010767703,"about_ca_topic_score_gemma":0.00018749184,"teacher_disagreement_score":0.9675746,"about_ca_system_score_codex":0.00008373987,"about_ca_system_score_gemma":0.0058380477,"threshold_uncertainty_score":0.99979794},"labels":[],"label_agreement":null},{"id":"W2139585567","doi":"10.1186/1756-8722-6-17","title":"A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Prasugrel; Medicine; Placebo; Thienopyridine; Internal medicine; Clinical endpoint; P2Y12; Randomized controlled trial; Gastroenterology; Clopidogrel; Myocardial infarction; Pathology","score_opus":0.012846710098927794,"score_gpt":0.30613434439156234,"score_spread":0.29328763429263455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139585567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364984,0.00041839186,0.000032023443,0.0014579947,0.0004784994,0.0031075175,0.0000017423242,0.000008188127,0.0008458054],"genre_scores_gemma":[0.9990177,0.00010122198,0.0004405906,0.00023013986,0.000032371587,0.00009063473,0.0000058623327,0.000024122097,0.000057360565],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99741924,0.00040328593,0.0012809869,0.00021586053,0.00032824246,0.00035238097],"domain_scores_gemma":[0.996984,0.00062656123,0.0010873867,0.0002276428,0.0007568738,0.00031752835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004183248,0.00022947011,0.0016608611,0.00041131835,0.000038425846,0.0000058742116,0.00015339979,0.00024759446,0.00020475606],"category_scores_gemma":[0.0003384832,0.00014238083,0.00019106413,0.00020846806,0.00028794346,0.00013709339,0.000048384376,0.0006554058,0.000028692722],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90257967,0.022548607,0.0700536,0.00013012654,0.00054669625,0.0008707623,0.001958877,0.000046410405,0.000032948876,0.00003871883,0.0005699128,0.00062367576],"study_design_scores_gemma":[0.976829,0.014432789,0.0019874459,0.0001556587,0.0010906744,0.00011757831,0.0047954633,0.00019550296,0.000094402596,0.000014086007,0.0001566071,0.0001308187],"about_ca_topic_score_codex":0.00012393243,"about_ca_topic_score_gemma":0.00007690763,"teacher_disagreement_score":0.074249305,"about_ca_system_score_codex":0.000116437106,"about_ca_system_score_gemma":0.0004055799,"threshold_uncertainty_score":0.5806122},"labels":[],"label_agreement":null},{"id":"W2143090141","doi":"10.1186/1756-8722-6-63","title":"High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Haemophilia; Internal medicine; Cohort; Retrospective cohort study; Hematology; Surgery","score_opus":0.022850582862280533,"score_gpt":0.293730886017961,"score_spread":0.27088030315568046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143090141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716556,0.00036028345,0.0000048837996,0.0010125979,0.00030954336,0.0011008066,0.0000019478416,0.000005428042,0.000038920287],"genre_scores_gemma":[0.99935997,0.00012327767,0.00023050682,0.00006451033,0.00006902623,0.00001964726,0.000002492261,0.000019219397,0.000111373316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740165,0.00038808282,0.0013815789,0.0001742859,0.00037633808,0.00027808928],"domain_scores_gemma":[0.9965433,0.00071800116,0.0014018053,0.00029959067,0.0009489615,0.00008836943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051905547,0.00016746951,0.0012267322,0.00023171693,0.0000784755,0.0000048396714,0.00022056294,0.00018254417,0.000054692173],"category_scores_gemma":[0.00046731115,0.0001074737,0.0001626033,0.00023655622,0.0003019516,0.00013278199,0.00008040669,0.00038543908,0.0000047418876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038540184,0.003999379,0.880215,0.00044052838,0.0006322191,0.00095104513,0.0014489217,0.00002892637,0.10738329,0.000023627084,0.00003986965,0.000983189],"study_design_scores_gemma":[0.007593409,0.009110887,0.9291583,0.0005001468,0.00020526348,0.002144826,0.0006338075,0.000018196322,0.05051079,0.0000450301,0.0000071250647,0.00007225578],"about_ca_topic_score_codex":0.00009295598,"about_ca_topic_score_gemma":0.000077154255,"teacher_disagreement_score":0.0568725,"about_ca_system_score_codex":0.00019960442,"about_ca_system_score_gemma":0.00032314105,"threshold_uncertainty_score":0.43826503},"labels":[],"label_agreement":null},{"id":"W2145273779","doi":"10.1186/1756-8722-5-s1-a7","title":"Targeting p53 by small molecule p53 activators in multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Mdm2; Cancer research; Cell cycle checkpoint; Chronic lymphocytic leukemia; Ubiquitin ligase; Multiple myeloma; Leukemia; Apoptosis; Cell cycle; Myeloid leukemia; Medicine; Biology; Cancer; Ubiquitin; Immunology; Internal medicine; Gene","score_opus":0.019457618634709878,"score_gpt":0.28950177208906747,"score_spread":0.2700441534543576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145273779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850569,0.008121851,0.0013140986,0.0025636523,0.0011577794,0.00027979317,0.0000033095566,0.000025501438,0.0014771583],"genre_scores_gemma":[0.9939059,0.00018389164,0.004337415,0.0011578267,0.00027758564,0.000013837409,0.000009393249,0.000050093255,0.00006407868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974645,0.0003281972,0.0010314013,0.00021210503,0.00022538603,0.00073840405],"domain_scores_gemma":[0.9980011,0.00043403733,0.00079551735,0.00021707607,0.00018128287,0.00037097026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087847636,0.00024202796,0.0011251767,0.00040785645,0.00005993412,0.0000049838695,0.00019105287,0.0006078069,0.00016845338],"category_scores_gemma":[0.0011086238,0.00021626415,0.0002253412,0.00029274574,0.0001709256,0.00013264015,0.00008388284,0.0012248653,0.000046120887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017344248,0.0019864666,0.16094856,0.0001229364,0.00048121827,0.0031601049,0.0016281753,0.000047097245,0.79252654,0.00045135934,0.032778747,0.0041344026],"study_design_scores_gemma":[0.02553025,0.0054547335,0.022920834,0.00058279064,0.0007461251,0.06427477,0.0027964774,0.00043812458,0.6095945,0.000190667,0.26656213,0.0009085488],"about_ca_topic_score_codex":0.000032954864,"about_ca_topic_score_gemma":0.000030760653,"teacher_disagreement_score":0.23378338,"about_ca_system_score_codex":0.00060791435,"about_ca_system_score_gemma":0.0005142356,"threshold_uncertainty_score":0.8818996},"labels":[],"label_agreement":null},{"id":"W2147881986","doi":"10.1186/1756-8722-5-67","title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","year":2012,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Takeda Oncology; European Society for Medical Oncology; National Comprehensive Cancer Network","keywords":"Rituximab; Medicine; Bortezomib; Internal medicine; Follicular lymphoma; International Prognostic Index; Hazard ratio; Lymphoma; Clinical endpoint; Oncology; Surgery; Randomized controlled trial; Confidence interval; Multiple myeloma","score_opus":0.015188422910360717,"score_gpt":0.31005445830081385,"score_spread":0.29486603539045314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147881986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917402,0.0028053566,0.00032019085,0.0007062798,0.0015370832,0.0024917952,0.000107807,0.000031277847,0.00025997043],"genre_scores_gemma":[0.99330425,0.00062873005,0.005039078,0.00027565495,0.00029903807,0.0001967021,0.00016024784,0.00006912028,0.000027191149],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99154353,0.0020998395,0.0034921616,0.00064980774,0.0010529857,0.0011616907],"domain_scores_gemma":[0.9886702,0.004714754,0.0041396734,0.0007155295,0.001121646,0.0006382202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029513964,0.00078345713,0.01076938,0.002136573,0.00016657852,0.000022581919,0.00031685602,0.0008635553,0.00024319132],"category_scores_gemma":[0.0022367463,0.00050951116,0.0018342945,0.0015918404,0.0008626358,0.00044026444,0.00012720595,0.0006659273,0.000046041725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83320093,0.0945292,0.04310078,0.00006998133,0.020696929,0.003558871,0.00093121885,0.000017680197,0.0000082843635,0.0009451435,0.00045058725,0.0024904031],"study_design_scores_gemma":[0.9188962,0.017444078,0.022860778,0.00019376852,0.037269242,0.0010612827,0.0004649872,0.00018853672,0.0006252129,0.000050715822,0.0005328034,0.0004124114],"about_ca_topic_score_codex":0.00085860153,"about_ca_topic_score_gemma":0.0005771228,"teacher_disagreement_score":0.08569527,"about_ca_system_score_codex":0.0019894731,"about_ca_system_score_gemma":0.0015510153,"threshold_uncertainty_score":0.99973565},"labels":[],"label_agreement":null},{"id":"W2148565111","doi":"10.1186/1756-8722-4-37","title":"Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells","year":2011,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Peking Union Medical College; National Natural Science Foundation of China","keywords":"Stromal cell; Transfection; microRNA; Bone marrow; Cancer research; Hematology; Multiple myeloma; Cytotoxic T cell; Cell growth; Interleukin; Cell culture; Medicine; Biology; Immunology; Molecular biology; In vitro; Cytokine; Gene; Biochemistry","score_opus":0.022857659148931384,"score_gpt":0.3252212007589212,"score_spread":0.3023635416099898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148565111","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4402998,0.044772226,0.00037717327,0.4863647,0.005030589,0.0018975972,0.00010039742,0.0000802935,0.021077227],"genre_scores_gemma":[0.64624983,0.0066464115,0.031400483,0.2643713,0.006234063,0.0003287055,0.00054482627,0.00056434376,0.043660074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99467283,0.001020884,0.001840535,0.00061697955,0.000697957,0.0011508347],"domain_scores_gemma":[0.9955969,0.0012282865,0.0019190281,0.0005381489,0.0003885893,0.00032904887],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006687381,0.00061598315,0.002842841,0.0009890498,0.000100938916,0.00002703543,0.0006853454,0.0017226244,0.0010168466],"category_scores_gemma":[0.0002931821,0.0004609387,0.0004973877,0.00021061431,0.0005414215,0.00021379493,0.00018477326,0.004522976,0.00011031382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021815135,0.0006899024,0.002046291,0.0006059946,0.00042269283,0.04002933,0.00058682385,5.831529e-8,0.027061038,0.0000071909867,0.924604,0.0017651696],"study_design_scores_gemma":[0.0059977737,0.0010018005,0.00029313655,0.002393022,0.00023850134,0.0054259007,0.00015949243,0.0000014143465,0.22198564,0.00039126026,0.7617871,0.00032493068],"about_ca_topic_score_codex":0.000051644092,"about_ca_topic_score_gemma":0.0002592915,"teacher_disagreement_score":0.2219934,"about_ca_system_score_codex":0.0010160247,"about_ca_system_score_gemma":0.0010164448,"threshold_uncertainty_score":0.99989635},"labels":[],"label_agreement":null},{"id":"W2150291652","doi":"10.1186/1756-8722-2-28","title":"RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression","year":2009,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Canadian Institutes of Health Research; Saskatchewan Health Research Foundation","keywords":"Cancer research; Biology; Population; Medicine","score_opus":0.00950987039396989,"score_gpt":0.3002109589257798,"score_spread":0.2907010885318099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150291652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98639745,0.0069949757,0.00047512402,0.005200565,0.00048063006,0.0001821034,0.000012389515,0.0000095836285,0.0002472002],"genre_scores_gemma":[0.9967312,0.00044868345,0.001316527,0.0009333176,0.00035511752,0.0000045918027,0.00002081043,0.000020494912,0.00016924448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818677,0.00021178414,0.00063332747,0.0003276847,0.00024577798,0.00039463842],"domain_scores_gemma":[0.9983788,0.000024540845,0.0007407471,0.00031526957,0.0002634128,0.00027723715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000309025,0.00022914268,0.00050526997,0.00015346812,0.00014138987,0.0000220576,0.00029245057,0.00034464672,0.00013326682],"category_scores_gemma":[0.00010538622,0.00019068099,0.00028210296,0.000087642824,0.00013299545,0.000014197432,0.000088859204,0.0002687149,0.0000107309415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015878229,0.00051805266,0.008133133,0.000036966532,0.00015989969,0.00072908885,0.00013640277,0.00006975644,0.98231745,0.00006465836,0.0030495813,0.0031971661],"study_design_scores_gemma":[0.0025679022,0.0017015764,0.040728547,0.000057186076,0.00018781076,0.0011657465,0.000049125672,0.00007611626,0.9356076,0.0012808066,0.016331015,0.00024657967],"about_ca_topic_score_codex":0.000001479609,"about_ca_topic_score_gemma":0.0000017904562,"teacher_disagreement_score":0.046709884,"about_ca_system_score_codex":0.000041249394,"about_ca_system_score_gemma":0.00024584978,"threshold_uncertainty_score":0.77757454},"labels":[],"label_agreement":null},{"id":"W2152127926","doi":"10.1186/1756-8722-7-1","title":"Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK; National Cancer Institute; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Docetaxel; Carboplatin; Rash; Internal medicine; Paclitaxel; Erlotinib; Nausea; Febrile neutropenia; Pharmacology; Oncology; Neutropenia; Chemotherapy; Cisplatin; Cancer; Epidermal growth factor receptor","score_opus":0.01163486206297069,"score_gpt":0.31655276048701236,"score_spread":0.30491789842404166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152127926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681515,0.0003019453,0.00017838253,0.00040283223,0.0014374582,0.00056091894,0.000017720227,0.0000055659834,0.0002800096],"genre_scores_gemma":[0.9975426,0.000020110427,0.0015151995,0.00039160196,0.00039065586,0.00002766951,0.0000107589085,0.000039223665,0.00006215405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968957,0.0006155442,0.0013260941,0.00034800457,0.00034117993,0.00047348026],"domain_scores_gemma":[0.9969441,0.00023539203,0.0018034895,0.00045162672,0.00043067886,0.00013471238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008488764,0.00030001966,0.0012057777,0.00015814014,0.000071348935,0.000008629167,0.0005528922,0.00043768116,0.00004037027],"category_scores_gemma":[0.0010256802,0.00018828064,0.00022244494,0.00022590895,0.00044447515,0.000018005345,0.00014644237,0.00052249123,0.0000021607018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63769853,0.012183087,0.07999736,0.00037771548,0.001537305,0.00038960454,0.0012910629,0.0032119055,0.2300812,0.00071785646,0.0108722225,0.021642148],"study_design_scores_gemma":[0.5013989,0.12101757,0.0041101966,0.0005700686,0.0004491488,0.0014108967,0.00040296634,0.00014322839,0.33374438,0.00037469654,0.03542234,0.00095560524],"about_ca_topic_score_codex":0.000012501418,"about_ca_topic_score_gemma":0.00018959118,"teacher_disagreement_score":0.13629964,"about_ca_system_score_codex":0.00015335002,"about_ca_system_score_gemma":0.0011457979,"threshold_uncertainty_score":0.7677862},"labels":[],"label_agreement":null},{"id":"W2161274278","doi":"10.1186/1756-8722-6-23","title":"Targeting p53 by small molecules in hematological malignancies","year":2013,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital","funders":"Leukemia and Lymphoma Society","keywords":"Hematology; Hematologic Neoplasms; Medicine; Internal medicine; Oncology; Cancer research; Cancer","score_opus":0.04812151298779321,"score_gpt":0.3468081397408627,"score_spread":0.2986866267530695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161274278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007504288,0.9944968,0.000651075,0.00091836485,0.00095988467,0.0010684868,0.000012299832,0.000036538437,0.0011060988],"genre_scores_gemma":[0.000088058274,0.9894806,0.009340595,0.0004728659,0.00019919455,0.000116784984,0.000052486354,0.00011032934,0.00013909252],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937883,0.0009894554,0.0034052713,0.0005677555,0.0003525046,0.00089672743],"domain_scores_gemma":[0.9948005,0.00094093214,0.0030987265,0.00041510677,0.00037493993,0.00036977124],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010494746,0.0007481806,0.0081261825,0.00091886305,0.000058461952,0.000018208504,0.0005638203,0.002556123,0.00045512558],"category_scores_gemma":[0.0013181133,0.0005461015,0.001224972,0.0005003671,0.0004185891,0.000069448084,0.00021443781,0.0030777985,0.00018137715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005210045,0.00343713,0.00039857268,0.038900275,0.0036111246,0.07847048,0.00046045313,0.00002013223,0.0015306224,0.004515268,0.18302652,0.6851084],"study_design_scores_gemma":[0.0016185377,0.0013450834,0.0000031896027,0.0075132838,0.0013853803,0.10067454,0.0001109764,0.000009568681,0.000089836096,0.00014215319,0.88674194,0.00036553957],"about_ca_topic_score_codex":0.000018794746,"about_ca_topic_score_gemma":0.000013663678,"teacher_disagreement_score":0.7037154,"about_ca_system_score_codex":0.00089203106,"about_ca_system_score_gemma":0.0022978352,"threshold_uncertainty_score":0.99969906},"labels":[],"label_agreement":null},{"id":"W2162251295","doi":"10.1186/1756-8722-1-20","title":"First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting","year":2008,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical Oncology; Medicine; Survivin; Hematology; Internal medicine; Oncology; Clinical trial; Cancer","score_opus":0.045818258317923,"score_gpt":0.3651020862418146,"score_spread":0.3192838279238916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162251295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843077,0.0075705503,0.0000188903,0.005606082,0.0014088498,0.0003466622,0.000030380612,0.000009319397,0.00070157374],"genre_scores_gemma":[0.9923856,0.006070689,0.0007505878,0.00037249975,0.000053729036,0.000009701964,0.000010228048,0.000027212815,0.00031972365],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99057317,0.002917585,0.005346346,0.00036615063,0.0001463631,0.0006503873],"domain_scores_gemma":[0.98760617,0.0044315937,0.006867454,0.00057172653,0.0004754743,0.00004760355],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0033123728,0.00034260377,0.0034515487,0.0004501724,0.00022346994,0.0000014637692,0.0009906499,0.0010427971,0.00016694913],"category_scores_gemma":[0.0014027508,0.0002477466,0.0010398693,0.00064053055,0.004076366,0.00012230693,0.0002059384,0.00144994,0.0000074715263],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07055964,0.030325027,0.16184992,0.00048927206,0.0058124606,0.0012228924,0.02065375,0.00057486363,0.5958507,0.0021646796,0.1023891,0.008107672],"study_design_scores_gemma":[0.067674175,0.022873126,0.13339752,0.00082971697,0.0003497938,0.006797718,0.0032710778,0.000054806795,0.26405257,0.00023910898,0.4999136,0.00054678693],"about_ca_topic_score_codex":0.0006785676,"about_ca_topic_score_gemma":0.0008707222,"teacher_disagreement_score":0.3975245,"about_ca_system_score_codex":0.00022821318,"about_ca_system_score_gemma":0.0013190247,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W2168535495","doi":"10.1186/1756-8722-4-38","title":"Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4","year":2011,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; University of Nevada, Las Vegas","keywords":"Stem cell; Haematopoiesis; Progenitor cell; Hematology; Hematopoietic stem cell; Biology; Cancer research; Internal medicine; Cell biology; Medicine","score_opus":0.008481752249099743,"score_gpt":0.2282313107589216,"score_spread":0.21974955850982186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168535495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986498,0.009913435,0.00044654886,0.00024444726,0.0010258642,0.00020332269,0.000012707502,0.000009522677,0.0016461657],"genre_scores_gemma":[0.99641097,0.0020808731,0.0006447507,0.00025206857,0.00014030343,0.000012975372,0.000007138857,0.000031027677,0.0004199202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779373,0.00035333756,0.0009923801,0.00026179073,0.00020881381,0.00038995442],"domain_scores_gemma":[0.99783623,0.0001140419,0.0012468472,0.00032365945,0.00031230747,0.00016693452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044629793,0.00024997938,0.00072499795,0.00008553316,0.00007463695,0.0000047521603,0.0006061954,0.00065822515,0.000054392207],"category_scores_gemma":[0.000011591265,0.0001610496,0.00031120153,0.00014045827,0.00029940112,0.000007069657,0.00011230371,0.0003860412,0.000020547093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005115162,0.00042901165,0.0002574619,0.00006805709,0.0005761295,0.000089179004,0.00073915423,0.000010841327,0.99098694,0.000051151288,0.005785542,0.0004950365],"study_design_scores_gemma":[0.0015287554,0.0020832545,0.000015552823,0.000022115724,0.00022127997,0.0017565291,0.0006382926,0.0000032314522,0.98645955,0.000056190504,0.0070517026,0.00016356018],"about_ca_topic_score_codex":0.000012422271,"about_ca_topic_score_gemma":0.00000952693,"teacher_disagreement_score":0.0099129565,"about_ca_system_score_codex":0.000055221833,"about_ca_system_score_gemma":0.00051016646,"threshold_uncertainty_score":0.6567412},"labels":[],"label_agreement":null},{"id":"W2511378889","doi":"10.1186/s13045-016-0312-z","title":"Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy","year":2016,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Ladies Leukemia League; Stichting Kinderen Kankervrij; Children’s Oncology Group; Takeda Oncology; National Cancer Institute; National Institutes of Health","keywords":"Bortezomib; Hematology; Medicine; Chemotherapy; Internal medicine; Oncology; Proteasome inhibitor; Proteasome; Multiple myeloma; Biology; Genetics","score_opus":0.00805399605000955,"score_gpt":0.2607409526006481,"score_spread":0.25268695655063855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511378889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715596,0.0005382207,0.0008133892,0.0008220533,0.00015051386,0.00025201167,0.000008044389,0.000007640138,0.0002521403],"genre_scores_gemma":[0.99704176,0.000608155,0.0017472934,0.00032938516,0.00016279581,0.000017923248,0.000009489914,0.000023916906,0.000059304246],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978942,0.00044664336,0.0007342584,0.00036155598,0.00016273074,0.0004006108],"domain_scores_gemma":[0.99829453,0.0002168431,0.00084639306,0.0002462035,0.00023865546,0.00015739202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010540171,0.00023304838,0.0008349309,0.00043028127,0.00007443599,0.000010712032,0.000202347,0.00052506104,0.000033273325],"category_scores_gemma":[0.00046742652,0.0001679355,0.00021435849,0.00032195702,0.00015372699,0.000019709549,0.00012864024,0.00030964144,0.0000029066462],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012982951,0.00021177031,0.5498076,0.000016418935,0.0003959566,0.00011608079,0.0001888604,0.0000020977131,0.431141,0.000019794086,0.00021609537,0.016585995],"study_design_scores_gemma":[0.009665361,0.0032095467,0.23908141,0.00011818986,0.00038389233,0.0007689059,0.00012699154,0.000015584463,0.74351925,0.00033289572,0.00236987,0.0004081021],"about_ca_topic_score_codex":0.00000764071,"about_ca_topic_score_gemma":0.000073350384,"teacher_disagreement_score":0.31237823,"about_ca_system_score_codex":0.000104401915,"about_ca_system_score_gemma":0.00023436967,"threshold_uncertainty_score":0.6848211},"labels":[],"label_agreement":null},{"id":"W2551670998","doi":"10.1186/s13045-016-0349-z","title":"A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma","year":2016,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Institute of Cancer Research; China Scholarship Council; University of Alberta; University of Ottawa; Li Ka Shing Foundation","keywords":"Regulator; Wnt signaling pathway; Cancer research; Biology; SOX2; Cell culture; Molecular biology; Transcriptional regulation; Lymphoma; Cell growth; Gene expression; Transcription factor; Cell biology; Signal transduction; Gene; Immunology; Genetics","score_opus":0.01148644348260239,"score_gpt":0.26496089130228523,"score_spread":0.2534744478196828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551670998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983228,0.0050235027,0.00011786405,0.009292678,0.0006297969,0.0005095307,0.000021141008,0.000018157763,0.0011593155],"genre_scores_gemma":[0.9973388,0.0007438194,0.0004265956,0.00094387826,0.00019321025,0.000044972752,0.000013856537,0.00003804549,0.00025683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688804,0.00052320823,0.001187174,0.00038640885,0.0003208258,0.00069436803],"domain_scores_gemma":[0.99581397,0.0021657874,0.0010927233,0.00023693309,0.00045622987,0.00023437217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060694065,0.00037254515,0.0012967044,0.0004566272,0.00016570227,0.000017640907,0.00023718915,0.00037807555,0.00008586778],"category_scores_gemma":[0.0002785504,0.00020431499,0.00035434382,0.00035823465,0.00023103844,0.00020216327,0.00010739602,0.0002483019,0.00013110042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009362391,0.018056063,0.8723181,0.00026887737,0.0013408331,0.02469845,0.0056555006,0.000019205734,0.040435545,0.007935785,0.0067493236,0.013159952],"study_design_scores_gemma":[0.058130823,0.011492116,0.7576106,0.0011046329,0.0016719031,0.026631884,0.0021005983,0.00013243902,0.13689841,0.001795999,0.0018524445,0.0005781194],"about_ca_topic_score_codex":0.00018528433,"about_ca_topic_score_gemma":0.00070044294,"teacher_disagreement_score":0.11470745,"about_ca_system_score_codex":0.0013529995,"about_ca_system_score_gemma":0.0008784343,"threshold_uncertainty_score":0.8331723},"labels":[],"label_agreement":null},{"id":"W2551906795","doi":"10.1186/s13045-016-0354-2","title":"High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide","year":2016,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Hematology; Oncology; Refractory (planetary science); Thalidomide; Immunohistochemistry; Biology","score_opus":0.013447504030600493,"score_gpt":0.25234843161951775,"score_spread":0.23890092758891726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551906795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641784,0.00066623464,0.0015780744,0.029993374,0.00090897834,0.0020146794,0.0005379639,0.000016239383,0.00010605498],"genre_scores_gemma":[0.9598557,0.00017816418,0.007899858,0.024467153,0.0033244975,0.00041905983,0.0007742638,0.00025353066,0.0028277982],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966784,0.0005396614,0.001317154,0.0005231923,0.00038274642,0.0005588103],"domain_scores_gemma":[0.9948519,0.0003743927,0.0030008918,0.00044980802,0.001195824,0.00012718874],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00032200606,0.0004995512,0.0014649254,0.00029646532,0.000095321346,0.000012802005,0.0004918827,0.0019576014,0.00009953686],"category_scores_gemma":[0.0007585727,0.00032736507,0.0003930089,0.00009161696,0.00031178218,0.000024234489,0.000108508,0.00081529364,0.000006331246],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006312691,0.00074811134,0.022016415,0.0006060654,0.00096661417,0.00025163929,0.00008853244,0.0000013680371,0.41119543,0.000020009122,0.55519176,0.0026013562],"study_design_scores_gemma":[0.006937195,0.0076315133,0.00034565284,0.0005099323,0.00012943953,0.00017101254,0.000016529253,8.8644543e-7,0.51195633,0.000045423378,0.47192836,0.00032776356],"about_ca_topic_score_codex":0.000010408563,"about_ca_topic_score_gemma":0.000013294071,"teacher_disagreement_score":0.100760885,"about_ca_system_score_codex":0.00012617014,"about_ca_system_score_gemma":0.0007643838,"threshold_uncertainty_score":0.99991786},"labels":[],"label_agreement":null},{"id":"W2586463853","doi":"10.1186/s13045-017-0413-3","title":"Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia","year":2017,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Toronto; St. Michael's Hospital","funders":"Ministry of Education of the People's Republic of China; Canadian Institutes of Health Research; European Hematology Association; China Scholarship Council; Canadian Blood Services; Anhui Medical University","keywords":"Platelet; Immune thrombocytopenia; Medicine; Immunology; Clearance; Hematology; Immune system; Biomarker; Asialoglycoprotein receptor; Internal medicine; In vitro; Biology","score_opus":0.030693644630915735,"score_gpt":0.32656672953132027,"score_spread":0.29587308490040454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586463853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60831004,0.00935686,0.0006772948,0.37839618,0.0010651703,0.0014222891,0.000038684342,0.000019910838,0.0007135592],"genre_scores_gemma":[0.9559775,0.0028510503,0.008377506,0.029334309,0.0016681069,0.00007216891,0.00048534237,0.00018923238,0.0010448069],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775153,0.00010661876,0.0011970514,0.00027289081,0.00026301,0.0004088745],"domain_scores_gemma":[0.9940639,0.0014125513,0.003444933,0.00043286546,0.0005769437,0.000068803965],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00034752398,0.0004059744,0.0036271994,0.00036162286,0.00017018676,0.000013779313,0.00032659175,0.0014467157,0.000113245354],"category_scores_gemma":[0.00026473094,0.00026470656,0.00048348238,0.00006469525,0.00044190258,0.00011364016,0.000037636644,0.0012902227,0.000009069417],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032474224,0.00473966,0.030304829,0.002833579,0.027200771,0.09362373,0.0021766317,0.000077868615,0.0010673975,0.0003923435,0.7831731,0.02193588],"study_design_scores_gemma":[0.0553833,0.030989911,0.006217548,0.002144919,0.0061774505,0.11675214,0.00013080433,0.000062381354,0.0045085927,0.0024760277,0.7745261,0.00063079013],"about_ca_topic_score_codex":0.000020776683,"about_ca_topic_score_gemma":0.000037629943,"teacher_disagreement_score":0.34906188,"about_ca_system_score_codex":0.00015292854,"about_ca_system_score_gemma":0.0006183498,"threshold_uncertainty_score":0.9999805},"labels":[],"label_agreement":null},{"id":"W2589237569","doi":"10.1186/s13045-017-0417-z","title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Incyte","keywords":"Ruxolitinib; Medicine; Placebo; Myelofibrosis; Internal medicine; Randomized controlled trial; Population; Adverse effect; Clinical endpoint; Surgery; Pathology; Bone marrow","score_opus":0.03706328763014617,"score_gpt":0.3607162889532588,"score_spread":0.32365300132311264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589237569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981016,0.00061801693,0.00033244723,0.0076525873,0.0006862181,0.009047818,0.00008063742,0.000014592455,0.0005516796],"genre_scores_gemma":[0.9932414,0.00048156217,0.002598553,0.0005543439,0.0006968546,0.0021239624,0.00012746727,0.000050186773,0.00012564322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970184,0.00039351368,0.0012908498,0.00039711304,0.00038969197,0.0005104381],"domain_scores_gemma":[0.991873,0.0031561265,0.0033979502,0.0006491172,0.00062701636,0.00029675508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007826844,0.00048633304,0.003791041,0.00013758872,0.0005679564,0.00009103011,0.00032919456,0.00029368175,0.00019945843],"category_scores_gemma":[0.00033798648,0.00020912109,0.0006683623,0.000043078493,0.00067862327,0.00018425344,0.000046411966,0.0003310748,0.000015924663],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.877329,0.006135759,0.10490894,0.000019513205,0.0064006844,0.0004961859,0.0002794787,0.0000016130633,0.0000033958117,0.0013007583,0.00055031583,0.0025743602],"study_design_scores_gemma":[0.94412327,0.04277953,0.0026750606,0.00026067137,0.0064780484,0.0006578089,0.000096023556,0.000011357966,0.0005167343,0.000121392506,0.00209031,0.00018978577],"about_ca_topic_score_codex":0.00004846359,"about_ca_topic_score_gemma":0.00029513348,"teacher_disagreement_score":0.10223388,"about_ca_system_score_codex":0.00029618724,"about_ca_system_score_gemma":0.00085408107,"threshold_uncertainty_score":0.8527711},"labels":[],"label_agreement":null},{"id":"W2616354644","doi":"10.1186/s13045-017-0465-4","title":"An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; University of Toronto; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; University of Texas Health Science Center at San Antonio; Children’s Oncology Group; Cancer Research Society; Texas Children's Hospital; National Cancer Institute; National Institutes of Health; Children's Hospital of Philadelphia","keywords":"MEG3; microRNA; Osteosarcoma; Methylation; Computational biology; DNA methylation; Biology; Long non-coding RNA; Bioinformatics; Cancer research; Oncology; Medicine; Genetics; Gene expression; RNA; Gene","score_opus":0.02975235449571328,"score_gpt":0.3830397856403506,"score_spread":0.35328743114463734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616354644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927981,0.0009516848,0.0001282198,0.0049849674,0.0005772068,0.00039798263,0.000037091464,0.000010515773,0.00011426145],"genre_scores_gemma":[0.9940668,0.0003689828,0.0041716667,0.0011626859,0.00011319312,0.000022998354,0.000047732447,0.000034929373,0.000011020423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970415,0.0002695937,0.0014702982,0.0004112105,0.00024207523,0.0005652972],"domain_scores_gemma":[0.9964014,0.0007650611,0.0014425426,0.00089222746,0.0001914217,0.00030731354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012830242,0.0002752193,0.0014399589,0.0002008755,0.00023286014,0.00003897042,0.00055270625,0.0004625282,0.000057785164],"category_scores_gemma":[0.0009757392,0.0002117913,0.00028400138,0.00004829826,0.00029528153,0.00017579933,0.0004349537,0.0006498665,0.000064152984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002905414,0.00200718,0.9459039,0.00004681891,0.00031513005,0.019321416,0.0003903122,0.000011628619,0.023549264,0.00007957439,0.00037419287,0.005095199],"study_design_scores_gemma":[0.017870799,0.0034699098,0.9312227,0.0002066824,0.00030466125,0.025828457,0.00031580316,0.0003536154,0.017488573,0.00016728273,0.0025470243,0.00022449263],"about_ca_topic_score_codex":0.00013303517,"about_ca_topic_score_gemma":0.0020757616,"teacher_disagreement_score":0.014965385,"about_ca_system_score_codex":0.00047114343,"about_ca_system_score_gemma":0.0003126681,"threshold_uncertainty_score":0.86365986},"labels":[],"label_agreement":null},{"id":"W2625950020","doi":"10.1186/s13045-017-0490-3","title":"Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"T-cell and B-cell Immunology","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Cancer Society; Cancer Research Society","keywords":"Immunology; Bone marrow; Transplantation; T cell; CD8; Stem cell; Haematopoiesis; Biology; Granzyme; Granzyme B; Lymphopoiesis; Immune system; Medicine; Internal medicine; Cell biology; Perforin","score_opus":0.015609888528913176,"score_gpt":0.2622641932477187,"score_spread":0.24665430471880553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625950020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97584975,0.008170729,0.000578539,0.0026993963,0.0068571824,0.00027783733,0.000010406897,0.000050661893,0.005505505],"genre_scores_gemma":[0.9955596,0.00083066785,0.00053651124,0.00027146764,0.000097988996,0.000017760894,0.000015445377,0.00004396079,0.0026266195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964611,0.0007582611,0.0014774197,0.00043546598,0.00009362563,0.00077415246],"domain_scores_gemma":[0.99586356,0.0008618519,0.0022693493,0.00070740073,0.00022298859,0.00007485335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001053645,0.0004254115,0.0016726365,0.00040998956,0.0007969475,0.00005781062,0.0012760336,0.0011578961,0.0004261307],"category_scores_gemma":[0.00012709189,0.0003541007,0.0007197453,0.00008321342,0.00070790923,0.0004925016,0.00018509144,0.0011829298,0.0005021081],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001280154,0.0008375677,0.005297163,0.00017964952,0.0010820536,0.0022990906,0.0023912664,0.0000034350605,0.9724406,0.0010096183,0.0042617857,0.00891763],"study_design_scores_gemma":[0.0077821226,0.004013771,0.0013326065,0.0002995913,0.00096378603,0.030997142,0.00225556,0.0000017325912,0.91887236,0.002235241,0.030682653,0.0005634507],"about_ca_topic_score_codex":0.00004479532,"about_ca_topic_score_gemma":0.000074482225,"teacher_disagreement_score":0.053568244,"about_ca_system_score_codex":0.00017333122,"about_ca_system_score_gemma":0.00043812397,"threshold_uncertainty_score":0.9998911},"labels":[],"label_agreement":null},{"id":"W2626414898","doi":"10.1186/s13045-017-0492-1","title":"Role of epigenetics-microRNA axis in drug resistance of multiple myeloma","year":2017,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"microRNA; Multiple myeloma; Epigenetics; Hematology; Drug resistance; Medicine; Internal medicine; Oncology; Drug; Cancer research; Bioinformatics; Pharmacology; Computational biology; Biology; Genetics; Gene","score_opus":0.0652217907511443,"score_gpt":0.4123141270484581,"score_spread":0.3470923362973138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626414898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007888647,0.98876065,0.0000051207858,0.00025834545,0.00024034076,0.00079342996,0.000043761516,0.0000040679024,0.0020056078],"genre_scores_gemma":[0.01809932,0.97715396,0.0039074584,0.00001341518,0.00010417379,0.000029620121,0.000020148154,0.000049331586,0.0006225787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99524885,0.00071729167,0.0027496128,0.00033047024,0.00041240934,0.000541358],"domain_scores_gemma":[0.9921748,0.001584987,0.0046526715,0.0007528506,0.00055803783,0.0002766494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010905123,0.00040851725,0.0069046565,0.0010243324,0.00005352234,0.0000049300093,0.0006883771,0.0007581735,0.00009349283],"category_scores_gemma":[0.0018586937,0.00030134854,0.000997119,0.00020656598,0.00061887904,0.00005867646,0.00017149073,0.0011129227,0.000021454725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002316736,0.0025771619,0.015104554,0.02641055,0.0028999215,0.007706994,0.00046152057,4.4710833e-7,0.00044426208,0.00029509354,0.001913394,0.93986934],"study_design_scores_gemma":[0.0050469064,0.0010989856,0.0021052256,0.014688319,0.0010866673,0.0054697944,0.000098253746,0.0000020925215,0.0010574155,0.00021046941,0.968952,0.000183863],"about_ca_topic_score_codex":0.0000743164,"about_ca_topic_score_gemma":0.0009390077,"teacher_disagreement_score":0.96703863,"about_ca_system_score_codex":0.00041401442,"about_ca_system_score_gemma":0.0028758538,"threshold_uncertainty_score":0.99994385},"labels":[],"label_agreement":null},{"id":"W2734041100","doi":"10.1186/s13045-017-0499-7","title":"The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"Priority Academic Program Development of Jiangsu Higher Education Institutions; Government of Jiangsu Province; Natural Science Foundation of Jiangsu Province; National Natural Science Foundation of China","keywords":"Apoptosis; Molecular biology; Biology; Flow cytometry; Ubiquitin; Immunoprecipitation; Cell growth; Multiple myeloma; Downregulation and upregulation; Cancer research; Chromatin immunoprecipitation; Cell culture; Chemistry; Gene expression; Immunology; Biochemistry; Promoter; Gene","score_opus":0.022622217207112476,"score_gpt":0.2876465876844599,"score_spread":0.2650243704773474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734041100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888475,0.0035767062,0.00007667116,0.0032138885,0.00053110754,0.00017267777,0.000007084457,0.0000058100004,0.0035685648],"genre_scores_gemma":[0.9974176,0.00067046063,0.0011501161,0.0002882518,0.00035435817,0.000014041926,0.000002918786,0.000019541842,0.00008266996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981228,0.00037138863,0.00066991674,0.00028527816,0.000137566,0.0004130132],"domain_scores_gemma":[0.99744016,0.0003198376,0.0012744933,0.00052423985,0.00028580756,0.00015548561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015303575,0.00021048944,0.0005210434,0.00004673054,0.00084437185,0.000088119275,0.0006442939,0.0004228609,0.000030441939],"category_scores_gemma":[0.0009664234,0.00014846597,0.00016010062,0.000026968999,0.00079086644,0.000019568939,0.00037320284,0.0004257155,0.000005302153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034499497,0.0001426504,0.012455342,0.000062239276,0.0001576769,0.00004125855,0.00037346507,0.0000021783355,0.9730801,0.0010715106,0.0010328942,0.011235715],"study_design_scores_gemma":[0.00095153134,0.0012385068,0.0024784887,0.000023375265,0.00005110434,0.0010073251,0.00064339355,0.000015621234,0.97438145,0.001295948,0.01775026,0.00016298342],"about_ca_topic_score_codex":0.000014303647,"about_ca_topic_score_gemma":0.000057469897,"teacher_disagreement_score":0.016717365,"about_ca_system_score_codex":0.000030050012,"about_ca_system_score_gemma":0.00028117863,"threshold_uncertainty_score":0.6494311},"labels":[],"label_agreement":null},{"id":"W2759277150","doi":"10.1186/s13045-017-0527-7","title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharma; Genentech; AOP Orphan; CTI Biopharma; Incyte; Baxalta; Ariad Pharmaceuticals; Gilead Sciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Hazard ratio; Randomized controlled trial; International Prognostic Scoring System; Clinical endpoint; Anemia; Hematology; Placebo; Survival analysis; Proportional hazards model; Clinical trial; Subgroup analysis; Surgery; Confidence interval; Bone marrow; Myelodysplastic syndromes; Pathology","score_opus":0.0497649413758295,"score_gpt":0.3819046456399105,"score_spread":0.332139704264081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759277150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959515,0.00043700924,0.00003315945,0.0023414597,0.0001446388,0.0005552035,0.00001297428,0.000006659825,0.000517421],"genre_scores_gemma":[0.99821156,0.00018784632,0.0011241088,0.00022791648,0.00007773624,0.000053633907,0.000020317499,0.000019936719,0.000076950484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843574,0.00011768375,0.00069531414,0.00023892723,0.0001743969,0.0003379592],"domain_scores_gemma":[0.99777174,0.00040018678,0.0009886815,0.00024874543,0.00039475854,0.00019586062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028546524,0.000229512,0.0014791689,0.00026215505,0.00026000012,0.000022632656,0.00012972132,0.00021836204,0.000037459362],"category_scores_gemma":[0.00026255357,0.00014585447,0.00013836399,0.000056412544,0.00025845692,0.00013474457,0.000059966198,0.0002232823,0.0000015304745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003991577,0.0017885235,0.989266,0.000076481934,0.0008727773,0.00069308816,0.00015620746,0.0000010690311,0.00009874493,0.00039346388,0.0001662262,0.002495863],"study_design_scores_gemma":[0.02005192,0.014038066,0.96073085,0.00025599438,0.0009152264,0.0012073513,0.000065400614,0.0000087274175,0.002265432,0.00006142451,0.00028059824,0.00011898476],"about_ca_topic_score_codex":0.00003207506,"about_ca_topic_score_gemma":0.00036469608,"teacher_disagreement_score":0.028535105,"about_ca_system_score_codex":0.0001517476,"about_ca_system_score_gemma":0.000253261,"threshold_uncertainty_score":0.5947773},"labels":[],"label_agreement":null},{"id":"W2766193356","doi":"10.1186/s13045-017-0538-4","title":"Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis","year":2017,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"microRNA; Oncomir; Multiple myeloma; Pathogenesis; Cancer research; Suppressor; Biology; Drug resistance; Hematology; Function (biology); Mechanism (biology); Bioinformatics; Gene; Medicine; Immunology; Genetics","score_opus":0.02445086020801732,"score_gpt":0.3420576218357852,"score_spread":0.31760676162776785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766193356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11644894,0.88272834,0.0000152258135,0.00003586007,0.0002689213,0.00032949224,0.000060651473,0.00000210199,0.000110482666],"genre_scores_gemma":[0.03679829,0.96129173,0.0014583938,0.00003529852,0.00023132627,0.0000310956,0.00006075471,0.0000594128,0.000033672528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99708843,0.0005676732,0.0015334308,0.00037619445,0.000112628746,0.00032161767],"domain_scores_gemma":[0.99587214,0.00020676636,0.0030753931,0.000501663,0.0002097017,0.00013431984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060811185,0.00037231337,0.0026040222,0.00037939133,0.000053661242,0.000012694571,0.00060484465,0.0008661617,0.000027811875],"category_scores_gemma":[0.00063892466,0.00031541075,0.0005466687,0.00006291748,0.0003633247,0.000009965505,0.00031960494,0.00037383914,0.000004155705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075427373,0.0007197578,0.0026327353,0.007992939,0.0012667746,0.00094416563,0.00013383862,0.0000034734537,0.33364877,0.00007542553,0.0013575442,0.6504703],"study_design_scores_gemma":[0.0016226689,0.0007112468,0.00078980037,0.0027859781,0.00071002194,0.0114037255,0.00005437794,0.000004264492,0.02014251,0.0000679726,0.961375,0.0003324385],"about_ca_topic_score_codex":0.0000075359335,"about_ca_topic_score_gemma":0.000073816365,"teacher_disagreement_score":0.96001744,"about_ca_system_score_codex":0.00008476638,"about_ca_system_score_gemma":0.0008334408,"threshold_uncertainty_score":0.9999298},"labels":[],"label_agreement":null},{"id":"W2795765610","doi":"10.1186/s13045-018-0589-1","title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway","year":2018,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Cancer Research Society; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Clinical trial; Hematology; PD-L1; Oncology; Immune system; Immunotherapy; Bioinformatics; Cancer research; Pharmacology; Internal medicine; Immunology; Biology","score_opus":0.12021023957209341,"score_gpt":0.43454534948459955,"score_spread":0.3143351099125061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795765610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041489262,0.951891,0.00036314467,0.0006473889,0.0011173557,0.0028264988,0.00007214392,0.000033258857,0.0015599683],"genre_scores_gemma":[0.08268453,0.8942865,0.018615114,0.00052262476,0.0024514126,0.00045746338,0.00019503369,0.00024282225,0.00054450805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992732,0.00233994,0.0024067299,0.0007249301,0.00070508476,0.0010913084],"domain_scores_gemma":[0.99364847,0.0021417101,0.002087448,0.00075821776,0.0006075181,0.0007566219],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018895761,0.0007380463,0.004652233,0.0010189369,0.00024399412,0.000037406408,0.0008962319,0.0010122549,0.00030499566],"category_scores_gemma":[0.0017876975,0.0004220363,0.0007350821,0.00049481564,0.00038800226,0.00022779581,0.00035272268,0.002194713,0.00015821264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038254573,0.0038071456,0.0044949125,0.0049634376,0.0022797317,0.03901923,0.0019713403,0.000081765065,0.00032773725,0.0003398655,0.0034046895,0.9354847],"study_design_scores_gemma":[0.010450981,0.016365964,0.002322455,0.016160721,0.0009248385,0.039168794,0.0010183905,0.0006649943,0.00081504014,0.0008184771,0.910504,0.0007853395],"about_ca_topic_score_codex":0.00008875379,"about_ca_topic_score_gemma":0.00027106825,"teacher_disagreement_score":0.93469936,"about_ca_system_score_codex":0.0009954324,"about_ca_system_score_gemma":0.0023242568,"threshold_uncertainty_score":0.99982315},"labels":[],"label_agreement":null},{"id":"W2807425977","doi":"10.1186/s13045-018-0618-0","title":"miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Natural Science Foundation of Guangdong Province; National Natural Science Foundation of China","keywords":"Glioblastoma; Autophagy; Cancer research; Hematology; Signal transduction; Temozolomide; Medicine; Pathway analysis; STAT3; Oncology; Chemistry; Internal medicine; Apoptosis; Gene; Gene expression; Biochemistry","score_opus":0.00963251872505067,"score_gpt":0.30180095130822965,"score_spread":0.292168432583179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807425977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923223,0.0048012636,0.00025285047,0.0017564519,0.0003319936,0.0002000602,0.0000044992303,0.00002410989,0.000306473],"genre_scores_gemma":[0.99647033,0.00011907179,0.0020078586,0.0009957242,0.0003229081,0.000005706728,0.0000022791933,0.000023214674,0.000052897645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798,0.0003030732,0.00081687036,0.0002639617,0.00020072088,0.00043535573],"domain_scores_gemma":[0.9982144,0.0005092607,0.0006589611,0.0001292477,0.00027298488,0.00021512757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009485811,0.00021597563,0.0010673903,0.00023306234,0.00009804065,0.000010576791,0.00010702162,0.00031225008,0.00018492433],"category_scores_gemma":[0.00036450333,0.0001750964,0.000116390984,0.00016394525,0.00049741333,0.00015254479,0.000050023544,0.00050388125,0.00001400745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023195392,0.001044049,0.0054718787,0.00013053614,0.00029032014,0.004524336,0.0020353214,7.336215e-7,0.9730843,0.00037610866,0.0025777742,0.00814511],"study_design_scores_gemma":[0.0034794877,0.0049918084,0.0015117183,0.00018701497,0.00008442093,0.0065725786,0.00052336726,0.000114227274,0.9753366,0.0014583399,0.0055792993,0.00016115289],"about_ca_topic_score_codex":0.000010839996,"about_ca_topic_score_gemma":0.000022706421,"teacher_disagreement_score":0.007983957,"about_ca_system_score_codex":0.000115326584,"about_ca_system_score_gemma":0.00044318743,"threshold_uncertainty_score":0.7140224},"labels":[],"label_agreement":null},{"id":"W2808120958","doi":"10.1186/s13045-018-0625-1","title":"Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Microvesicles; Exosome; Tumor microenvironment; Cancer research; Angiogenesis; Nonalcoholic fatty liver disease; Cell culture; Biology; Cell biology; Internal medicine; Chemistry; Medicine; microRNA; Fatty liver; Biochemistry; Disease","score_opus":0.009077484053554135,"score_gpt":0.2384835026020161,"score_spread":0.22940601854846196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808120958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829764,0.009300341,0.000489557,0.0006336959,0.00032596997,0.00022487693,0.0000073222745,0.000014644747,0.0007059725],"genre_scores_gemma":[0.9949575,0.000104523686,0.003428686,0.00078331283,0.00045793006,0.000016185488,0.000008050025,0.000048768805,0.00019503655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787813,0.00036310393,0.00069626595,0.0003623434,0.00020897598,0.0004911925],"domain_scores_gemma":[0.9980347,0.00007045815,0.0008066731,0.00038166367,0.0004566865,0.0002497823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043842115,0.0002757309,0.00061465235,0.00011210509,0.00014230632,0.000020427753,0.0004852058,0.00026737334,0.00007039197],"category_scores_gemma":[0.00025182276,0.00020782216,0.00016855936,0.000108994784,0.00085580384,0.000016933587,0.00013124774,0.00031047373,0.00003185812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011792255,0.00037292155,0.01931551,0.000060181355,0.00024664114,0.0006934359,0.00018702168,0.0000024896883,0.9666835,0.00008075488,0.010378764,0.0007995311],"study_design_scores_gemma":[0.0018405833,0.005390973,0.00032549843,0.000066562425,0.00013279839,0.0064607156,0.00026777125,0.000045521007,0.9550073,0.00008464244,0.030136505,0.00024111544],"about_ca_topic_score_codex":0.000008736104,"about_ca_topic_score_gemma":0.000028254894,"teacher_disagreement_score":0.01975774,"about_ca_system_score_codex":0.00006089946,"about_ca_system_score_gemma":0.00059244724,"threshold_uncertainty_score":0.84747416},"labels":[],"label_agreement":null},{"id":"W2891596347","doi":"10.1186/s13045-018-0661-x","title":"A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis","year":2018,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Fondazione Regionale per la Ricerca Biomedica; F. Hoffmann-La Roche","keywords":"Ruxolitinib; Vismodegib; Myelofibrosis; Medicine; Internal medicine; Hematology; Oncology; Phases of clinical research; Clinical trial; Bone marrow","score_opus":0.022472772919080175,"score_gpt":0.33131442023480595,"score_spread":0.3088416473157258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891596347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416677,0.000058902755,0.000037540343,0.05561579,0.00020700363,0.0023300503,0.000032465883,0.000004926374,0.000045656423],"genre_scores_gemma":[0.9795716,0.00008881878,0.0008286944,0.01906456,0.00020355648,0.00013066051,0.000047191486,0.000044526983,0.000020393694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636424,0.001012382,0.0013500449,0.0003992319,0.00048374492,0.00039036231],"domain_scores_gemma":[0.9950526,0.0022367479,0.0016318818,0.0003147923,0.00064576074,0.0001182704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007595635,0.00040703503,0.0023396227,0.0007562899,0.00006238073,0.000013454812,0.0002104433,0.00043021108,0.000053861684],"category_scores_gemma":[0.0003930008,0.00019973729,0.00007026058,0.00034235689,0.00035473466,0.00008385293,0.00009034917,0.0014690451,0.0000029981359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039841976,0.018857429,0.91649806,0.00016968495,0.0011485366,0.0033767396,0.0037198365,0.000005329461,0.0000022401002,0.000035953613,0.014284219,0.0020600068],"study_design_scores_gemma":[0.090852104,0.14399455,0.7569203,0.0012772251,0.0010475504,0.0007827032,0.00060783944,0.0000055741316,0.000109553126,0.00003193755,0.004162206,0.000208451],"about_ca_topic_score_codex":0.00010035905,"about_ca_topic_score_gemma":0.00083220867,"teacher_disagreement_score":0.15957776,"about_ca_system_score_codex":0.0004009659,"about_ca_system_score_gemma":0.0006423596,"threshold_uncertainty_score":0.81450504},"labels":[],"label_agreement":null},{"id":"W2947538095","doi":"10.1186/s13045-019-0731-8","title":"Emerging therapies for non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Natural Science Foundation of China","keywords":"Medicine; Hematology; Internal medicine; Lung cancer; Oncology; Intensive care medicine; Cancer; Medical physics","score_opus":0.04225786029802803,"score_gpt":0.44959770447566233,"score_spread":0.4073398441776343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947538095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013154671,0.99243027,0.00041775903,0.0012089578,0.0024089038,0.0015355994,0.000030070172,0.000009762507,0.0018271403],"genre_scores_gemma":[0.00004489826,0.99303377,0.0034378183,0.00039718472,0.0006020865,0.0002584988,0.000027133505,0.00007041693,0.0021282195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980208,0.000108203516,0.0011349383,0.000249718,0.00011956502,0.00036676158],"domain_scores_gemma":[0.9968074,0.00063730567,0.0018350456,0.00023122014,0.0003577997,0.00013124084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027617192,0.00034790704,0.003864545,0.00040507052,0.00007583675,0.000008444747,0.00020025762,0.0005845211,0.00018649001],"category_scores_gemma":[0.000040844887,0.00022563455,0.0010546211,0.00013603135,0.00006627101,0.000047798592,0.000033748667,0.00056407636,0.00001669767],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016337875,0.0006011992,0.0006521095,0.04738953,0.0071421755,0.00061540154,0.0011622842,0.0000034137897,0.00000726392,0.00035452447,0.0294102,0.91249853],"study_design_scores_gemma":[0.0026570717,0.0011313428,0.000008674425,0.006460416,0.017837182,0.0039001866,0.00017238877,0.0000068411746,0.000007953824,0.00002911285,0.9676272,0.00016160733],"about_ca_topic_score_codex":0.000012086474,"about_ca_topic_score_gemma":0.00001632908,"teacher_disagreement_score":0.93821704,"about_ca_system_score_codex":0.0007179265,"about_ca_system_score_gemma":0.0046355347,"threshold_uncertainty_score":0.920111},"labels":[],"label_agreement":null},{"id":"W2960151143","doi":"10.1186/s13045-019-0766-x","title":"K+-Cl− cotransporter 1 (KCC1): a housekeeping membrane protein that plays key supplemental roles in hematopoietic and cancer cells","year":2019,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"Canadian Institutes of Health Research; Kidney Foundation of Canada","keywords":"Housekeeping gene; Gene isoform; Cotransporter; Ouabain; Biology; Chemistry; Gene; Biochemistry; Gene expression","score_opus":0.05100090609693871,"score_gpt":0.3489391860766924,"score_spread":0.2979382799797537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960151143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015612776,0.98013616,0.00003004136,0.0010593021,0.0011979119,0.0016314833,0.00005514566,0.000020977945,0.0002561928],"genre_scores_gemma":[0.0029811133,0.9946244,0.0008006576,0.0007822311,0.00031718606,0.00012495114,0.000056813198,0.00009394832,0.00021872285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99595904,0.0005927644,0.0019905292,0.0005350275,0.00028321563,0.0006394005],"domain_scores_gemma":[0.9968443,0.00051772635,0.0019289863,0.0003286451,0.00012164742,0.00025870057],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006574225,0.00061110174,0.006369556,0.0008577025,0.000058960424,0.000010870968,0.00025170803,0.0013372021,0.0011478768],"category_scores_gemma":[0.00003873915,0.0004644608,0.00070026284,0.00022901302,0.0003238304,0.00010895164,0.00008305522,0.0018903977,0.00005976524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008167171,0.0060515013,0.008394201,0.29812497,0.009551329,0.048462074,0.0070088324,0.000032331016,0.019015184,0.002379666,0.019375093,0.57343763],"study_design_scores_gemma":[0.0054659955,0.0024259458,0.00005450101,0.018118542,0.0026545788,0.040077507,0.00040588717,0.0000051064326,0.0012749267,0.00004372759,0.92899823,0.00047504896],"about_ca_topic_score_codex":0.000027971602,"about_ca_topic_score_gemma":0.00022035945,"teacher_disagreement_score":0.90962315,"about_ca_system_score_codex":0.0004118548,"about_ca_system_score_gemma":0.0015406561,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W3005597885","doi":"10.1186/s13045-019-0842-2","title":"Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Nanjing Medical University; Government of Jiangsu Province; Jiangsu Science and Technology Department; National Natural Science Foundation of China","keywords":"Downregulation and upregulation; Cancer research; Metastasis; Biology; Carcinogenesis; microRNA; Lung cancer; Cancer; Long non-coding RNA; Small interfering RNA; Transfection; Cell migration; Cancer cell; Cell; Cell culture; Medicine; Pathology; Gene","score_opus":0.012067651255738717,"score_gpt":0.2867252466663514,"score_spread":0.2746575954106127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005597885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708509,0.022334903,0.0036738252,0.0022285285,0.00039900944,0.00026792646,0.000010687014,0.000012652129,0.00022159876],"genre_scores_gemma":[0.9933507,0.0012885176,0.0044292375,0.00035974575,0.00036074483,0.00001606331,0.000025698371,0.00004668751,0.00012262398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979887,0.00028078177,0.0007733888,0.0004491297,0.00015500071,0.00035300478],"domain_scores_gemma":[0.99799037,0.00009618409,0.001226163,0.00021013782,0.0002547725,0.0002223625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032778108,0.00026737273,0.00067440805,0.00006613041,0.00014476785,0.000023452398,0.0002282526,0.0005868325,0.00006461083],"category_scores_gemma":[0.00012928677,0.00024130462,0.00015557074,0.0001333752,0.00011994269,0.00002675155,0.00020088337,0.00040372583,0.0000010398456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004250433,0.00010414757,0.0017429013,0.00014184888,0.00017318041,0.000024829063,0.00057095574,0.00042442564,0.98041457,0.0000019442382,0.010924027,0.005052099],"study_design_scores_gemma":[0.0022233266,0.00080894696,0.00025693473,0.000102658436,0.00021921581,0.0004472836,0.00025102517,0.0014428515,0.98496825,0.000013784847,0.009034781,0.00023097462],"about_ca_topic_score_codex":0.000037002155,"about_ca_topic_score_gemma":0.000024237608,"teacher_disagreement_score":0.022499813,"about_ca_system_score_codex":0.000102197744,"about_ca_system_score_gemma":0.0003975824,"threshold_uncertainty_score":0.9840117},"labels":[],"label_agreement":null},{"id":"W3033283870","doi":"10.1186/s13045-020-00894-2","title":"PTENP1 is a ceRNA for PTEN: it’s CRISPR clear","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institutes of Health; National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Competing endogenous RNA; PTEN; CRISPR; Pseudogene; Biology; Computational biology; microRNA; Gene; Genetics; RNA; Bioinformatics; PI3K/AKT/mTOR pathway; Cancer research; Long non-coding RNA; Genome; Signal transduction","score_opus":0.03690685938457701,"score_gpt":0.3582913759758619,"score_spread":0.3213845165912849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033283870","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17698118,0.016936839,0.46342728,0.32656327,0.0038809397,0.00244021,0.00012977737,0.00006649026,0.009574021],"genre_scores_gemma":[0.95091724,0.0014094259,0.010125886,0.035358477,0.0014899005,0.000047949557,0.000023798051,0.00010882922,0.0005184624],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980076,0.00016211646,0.0007133452,0.00037743192,0.00023956275,0.0004999729],"domain_scores_gemma":[0.99825776,0.00007838536,0.000507734,0.00026366557,0.0005559056,0.00033657794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046345498,0.00021481313,0.00066879834,0.00011749461,0.00009322411,0.000016725826,0.0005443381,0.00062456884,0.00022471754],"category_scores_gemma":[0.0005820845,0.00020009793,0.00042921826,0.00013952809,0.00016148893,0.000007900244,0.00019871863,0.0005041187,0.000045371056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040821056,0.00023683022,0.00007253737,0.00010963214,0.00071454205,0.00045621532,0.00045652612,0.00008106192,0.567448,0.0017797758,0.41983545,0.0047273226],"study_design_scores_gemma":[0.0026602666,0.005952912,0.000013854539,0.000017528922,0.000101058744,0.0023463822,0.0003431327,0.0002228318,0.28715047,0.00038800776,0.7006264,0.00017717917],"about_ca_topic_score_codex":0.000004811494,"about_ca_topic_score_gemma":0.000014955345,"teacher_disagreement_score":0.7739361,"about_ca_system_score_codex":0.00007320759,"about_ca_system_score_gemma":0.0007611687,"threshold_uncertainty_score":0.81597567},"labels":[],"label_agreement":null},{"id":"W3033907870","doi":"10.1186/s13045-020-00900-7","title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Genentech; H. Lundbeck A/S; Juno Therapeutics; Incyte; F. Hoffmann-La Roche; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; Servier; TG Therapeutics; Amgen","keywords":"Obinutuzumab; Rituximab; Medicine; Internal medicine; Hematology; Diffuse large B-cell lymphoma; Oncology; CHOP; Lymphoma; Vincristine; Chemotherapy; Cyclophosphamide","score_opus":0.03923046234378376,"score_gpt":0.34559044681061596,"score_spread":0.3063599844668322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033907870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958908,0.00087714527,0.000033432694,0.0005375788,0.0000690715,0.002353009,0.000029263161,0.000008190568,0.00020150008],"genre_scores_gemma":[0.99860203,0.00018537573,0.0006079957,0.0003935914,0.000019886016,0.00009893473,0.000027844446,0.000024707706,0.00003962184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99572814,0.00078669883,0.0022532525,0.0003866876,0.00042997443,0.00041526582],"domain_scores_gemma":[0.9954468,0.0009304337,0.0024130708,0.00034430285,0.0005786264,0.00028674517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006823672,0.00035024827,0.006402831,0.00068711065,0.000051889932,0.000010643255,0.00037537486,0.00023486032,0.00013056234],"category_scores_gemma":[0.00037730084,0.00020809141,0.00029864025,0.0011889901,0.00020475332,0.00013428066,0.00017823714,0.00021400668,0.0000042683187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61887383,0.21135221,0.14964543,0.0001392242,0.009547419,0.004502116,0.004691429,0.000027046088,0.000016153157,0.00006456648,0.00036962476,0.0007709473],"study_design_scores_gemma":[0.93048024,0.040605582,0.010544276,0.00014314504,0.015506577,0.00031929955,0.0011970563,0.0006644366,0.00022909832,0.0000043985056,0.00015537109,0.00015051785],"about_ca_topic_score_codex":0.00038389128,"about_ca_topic_score_gemma":0.0006525065,"teacher_disagreement_score":0.3116064,"about_ca_system_score_codex":0.0008378341,"about_ca_system_score_gemma":0.0017677646,"threshold_uncertainty_score":0.84857213},"labels":[],"label_agreement":null},{"id":"W3037371046","doi":"10.1186/s13045-020-00922-1","title":"Oncolytic viruses for cancer immunotherapy","year":2020,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":354,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; Novo Nordisk Fonden; Biomedicum Helsinki-säätiö; Finska Läkaresällskapet; Helsingin Yliopisto","keywords":"Oncolytic virus; Immunotherapy; Virotherapy; Medicine; Clinical trial; Cancer; Cancer immunotherapy; Cancer research; Virology; Immunology; Virus; Oncology; Immune system; Internal medicine","score_opus":0.07781025988125306,"score_gpt":0.45459760217374107,"score_spread":0.376787342292488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037371046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000268737,0.9965383,0.00031057143,0.00071025174,0.001031732,0.00095120334,0.00006528812,0.00001431936,0.00010962623],"genre_scores_gemma":[0.000025668278,0.9955067,0.00094372465,0.0012862774,0.0015515857,0.00028679898,0.00002868638,0.00020425471,0.00016628734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635583,0.00074708083,0.0015680378,0.0004938084,0.00023667645,0.00059856067],"domain_scores_gemma":[0.9965295,0.00045352036,0.0018895848,0.00045325013,0.0004373684,0.00023674218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087939296,0.00053832325,0.003612032,0.00030091667,0.00008669164,0.000021188192,0.0010901589,0.0012661495,0.000107694235],"category_scores_gemma":[0.00032552166,0.0004254779,0.0014956425,0.00022138737,0.00028598408,0.000006167518,0.0001467544,0.00082337897,0.000023065764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036336915,0.0002530226,0.0000073097262,0.0022734485,0.002860335,0.00022750997,0.000041998057,0.0000039190354,0.0031018392,0.00008798413,0.018531147,0.9689778],"study_design_scores_gemma":[0.0016425245,0.01385591,2.2659063e-7,0.00078637956,0.0006010677,0.0027025526,0.000021785736,0.0000015249676,0.0026052392,0.000078921556,0.97736233,0.00034155828],"about_ca_topic_score_codex":0.000004333234,"about_ca_topic_score_gemma":0.000107221735,"teacher_disagreement_score":0.9686362,"about_ca_system_score_codex":0.00030495608,"about_ca_system_score_gemma":0.005730018,"threshold_uncertainty_score":0.9999066},"labels":[],"label_agreement":null},{"id":"W3042325035","doi":"10.1186/s13045-020-00929-8","title":"Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Hospital","funders":"Daiichi Sankyo Europe; Incyte; Agios Pharmaceuticals; Jazz Pharmaceuticals; European Hematology Association; Celgene; Gilead Sciences; Servier; Ariad Pharmaceuticals; Amgen; Pfizer; Astellas Pharma","keywords":"Medicine; Internal medicine; Cytarabine; Hazard ratio; Myeloid leukemia; Clinical trial; Oncology; Confidence interval","score_opus":0.0201375483975543,"score_gpt":0.31320000091298517,"score_spread":0.29306245251543084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042325035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468,0.00024590257,0.00012763495,0.004502644,0.00008962556,0.0003204184,0.000009346943,0.0000067625338,0.000017654986],"genre_scores_gemma":[0.99545944,0.00019011757,0.0018170553,0.0024062844,0.000068266534,0.000009623267,0.0000043271975,0.000028995688,0.000015867436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981433,0.00033404652,0.0006609466,0.00039751965,0.00014459604,0.00031957738],"domain_scores_gemma":[0.99864435,0.00032367854,0.00030715138,0.00015769107,0.00025005764,0.00031704007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006207774,0.000254764,0.0010491525,0.00014419969,0.000061804654,0.000013218509,0.00017964048,0.0002446997,0.0000025644597],"category_scores_gemma":[0.00044296926,0.00017174603,0.00006531657,0.00018302789,0.00017456297,0.000010109623,0.00015662097,0.00028523436,0.000002040597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039667968,0.00016632088,0.9376588,0.00000867348,0.0005805231,0.0003931863,0.00033280946,0.000047385078,0.018703658,0.0000076051765,0.00009948547,0.0023335835],"study_design_scores_gemma":[0.013222049,0.027995681,0.9492784,0.000054587406,0.00010502262,0.0003162173,0.00041773717,0.0000065412382,0.006401039,0.000006401163,0.001913221,0.0002831062],"about_ca_topic_score_codex":0.000010511016,"about_ca_topic_score_gemma":0.00011351942,"teacher_disagreement_score":0.02782936,"about_ca_system_score_codex":0.00006200972,"about_ca_system_score_gemma":0.00029766417,"threshold_uncertainty_score":0.70035994},"labels":[],"label_agreement":null},{"id":"W3042954004","doi":"10.1186/s13045-020-00930-1","title":"Role of CD47 in Hematological Malignancies","year":2020,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Cancer Research Society","keywords":"CD47; Phagocytosis; Hematology; Cancer research; Medicine; Immune system; Immunology; Tumor microenvironment; Cancer; Metastasis; Internal medicine","score_opus":0.0367411651691547,"score_gpt":0.3331643473625536,"score_spread":0.2964231821933989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042954004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012632296,0.9958688,0.000017681416,0.00023503265,0.00154311,0.00034877943,0.000016207216,0.00001447706,0.00069268985],"genre_scores_gemma":[0.006760589,0.99270463,0.00027372842,0.0000470728,0.00006871646,0.000024468267,0.000034762656,0.000036965488,0.000049073962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99409693,0.001592983,0.00334679,0.00035232434,0.0000811848,0.0005297913],"domain_scores_gemma":[0.9938036,0.0016127978,0.004013336,0.0003046623,0.00021035993,0.000055248605],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00086158805,0.00049664034,0.007559949,0.00070303644,0.000050406743,0.0000053000263,0.0007961629,0.0021237838,0.0003607154],"category_scores_gemma":[0.00072184234,0.00036025976,0.0011429072,0.00044306813,0.0005583248,0.000113437585,0.00023516342,0.0015495993,0.00016276393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043073235,0.0012740783,0.00032758992,0.0052423514,0.001901155,0.00094334583,0.000592986,0.0000018888405,0.005465681,0.016761102,0.0046443064,0.9624148],"study_design_scores_gemma":[0.0011306674,0.0011772854,0.000057282723,0.003315118,0.00072815013,0.020239905,0.00021058864,5.2082993e-7,0.0012872313,0.0005396609,0.9710599,0.0002536523],"about_ca_topic_score_codex":0.00000824168,"about_ca_topic_score_gemma":0.0000108065515,"teacher_disagreement_score":0.96641564,"about_ca_system_score_codex":0.00024237756,"about_ca_system_score_gemma":0.0012156374,"threshold_uncertainty_score":0.99988496},"labels":[],"label_agreement":null},{"id":"W3092142993","doi":"10.1186/s13045-020-00971-6","title":"High-throughput approaches for precision medicine in high-grade serous ovarian cancer","year":2020,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care","keywords":"Precision medicine; Serous carcinoma; Subtyping; Throughput; Personalized medicine; Medicine; Disease; Cancer; Ovarian cancer; Computer science; Oncology; Bioinformatics; Internal medicine; Biology; Pathology","score_opus":0.12953552146891298,"score_gpt":0.41269145702113835,"score_spread":0.2831559355522254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092142993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009525425,0.95721334,0.00038500794,0.03734477,0.002685546,0.0020530564,0.000052904936,0.00001876851,0.00015132134],"genre_scores_gemma":[0.00065254566,0.9858476,0.009601208,0.0008107104,0.0021866658,0.00062880875,0.00008412086,0.0001068471,0.0000815172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950708,0.00052653346,0.0027710912,0.00068360154,0.00036845796,0.0005794734],"domain_scores_gemma":[0.99432266,0.0019848598,0.0026944368,0.00041593311,0.00021671735,0.00036539862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088265305,0.00068396836,0.009411066,0.00068600423,0.00006604496,0.000009630847,0.00039455257,0.0012772124,0.00027338704],"category_scores_gemma":[0.0004407823,0.00043999922,0.0008273776,0.0005149171,0.00025711147,0.00008319887,0.00010198172,0.001318651,0.00001751796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006394631,0.0012612272,0.00023935891,0.00936736,0.0026401912,0.0047135307,0.0002978705,0.000008902469,6.4274224e-7,0.0073408214,0.021959541,0.9515311],"study_design_scores_gemma":[0.0101730395,0.0056681787,0.00014797391,0.015195343,0.0073966077,0.0115532195,0.000076917204,0.0000065693343,0.000008568798,0.001185891,0.9483158,0.00027188775],"about_ca_topic_score_codex":0.00024369576,"about_ca_topic_score_gemma":0.00024015906,"teacher_disagreement_score":0.9512592,"about_ca_system_score_codex":0.00187453,"about_ca_system_score_gemma":0.0031264622,"threshold_uncertainty_score":0.99980515},"labels":[],"label_agreement":null},{"id":"W3154559926","doi":"10.1186/s13045-021-01071-9","title":"Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cilag; Jazz Pharmaceuticals; Janssen Pharmaceuticals; Celgene; Karyopharm Therapeutics; Gilead Sciences; Bristol-Myers Squibb; Spectrum Pharmaceuticals; Amgen","keywords":"Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Peripheral neuropathy; Adverse effect; Lenalidomide; Proteasome inhibitor; Thalidomide; Hematology; Oncology; Gastroenterology; Surgery; Endocrinology","score_opus":0.025295061423108424,"score_gpt":0.3534062134124607,"score_spread":0.32811115198935226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154559926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9474654,0.00627711,0.000004316137,0.04402304,0.0002735599,0.0014980492,0.00003353384,0.000014948083,0.00041004573],"genre_scores_gemma":[0.94207776,0.0048875837,0.0064619654,0.042254098,0.0014875276,0.0002997958,0.0005115938,0.00027476225,0.001744924],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99438006,0.0020559637,0.001613728,0.0005727087,0.00057399424,0.00080354634],"domain_scores_gemma":[0.99115455,0.0062134997,0.0013881752,0.0004860498,0.0004583648,0.00029938028],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009997818,0.0006313744,0.004348439,0.0011311386,0.000053278658,0.000011172319,0.00021894978,0.0017648421,0.00011821426],"category_scores_gemma":[0.0026704788,0.00043241004,0.00047280433,0.0003895414,0.0003305004,0.00006578541,0.00009906137,0.0025434324,0.000016119138],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019694401,0.0031400113,0.54164386,0.0028126661,0.006673386,0.23806395,0.0003173641,0.0000028955255,0.0024743376,0.000004593547,0.073171206,0.112001345],"study_design_scores_gemma":[0.20699131,0.22441292,0.18067312,0.009183095,0.010342361,0.15382007,0.00016325628,0.0003599979,0.07805308,0.000071552415,0.13454427,0.0013849837],"about_ca_topic_score_codex":0.0001319233,"about_ca_topic_score_gemma":0.00008714064,"teacher_disagreement_score":0.36097074,"about_ca_system_score_codex":0.000723478,"about_ca_system_score_gemma":0.0010120024,"threshold_uncertainty_score":0.9998128},"labels":[],"label_agreement":null},{"id":"W3174383320","doi":"10.1186/s13045-021-01116-z","title":"Molecular pathogenesis of the myeloproliferative neoplasms","year":2021,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Research Board; Canadian Institute for Theoretical Astrophysics; Health Service Executive; Wellcome Trust; Wellcome","keywords":"Epigenetics; Disease; Biology; Myeloid; Myeloproliferative Disorders; Genetics; Bioinformatics; Cancer research; Medicine; Immunology; Gene; Internal medicine","score_opus":0.04123789998553555,"score_gpt":0.3755260178493881,"score_spread":0.33428811786385254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174383320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032813023,0.99214506,0.00003465909,0.0017077667,0.0010122873,0.000947442,0.000030751013,0.000006826991,0.0008339305],"genre_scores_gemma":[0.0007979954,0.99622434,0.001922662,0.0005405744,0.00020108742,0.0001114926,0.000019078576,0.000064491214,0.000118252865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948091,0.0015158993,0.0023775648,0.0004034303,0.0004900458,0.00040395497],"domain_scores_gemma":[0.9934127,0.001390679,0.0033681695,0.00060464366,0.0009976303,0.00022618473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005981313,0.0005946953,0.0075595793,0.00036581597,0.00009450314,0.000010199172,0.00039307072,0.0010060573,0.00023823237],"category_scores_gemma":[0.00084241014,0.0003232866,0.0024439765,0.0005381707,0.00035945716,0.000042556185,0.00020096613,0.0011214127,0.00001885348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003470874,0.005103,0.0042722556,0.017560385,0.017680895,0.02819164,0.0008039777,0.00001112237,0.00016076997,0.029644893,0.008065068,0.8881589],"study_design_scores_gemma":[0.0017518593,0.0021100338,0.00014289076,0.012501944,0.009391084,0.07283054,0.00011930807,0.0000011899724,0.0016111349,0.00010208462,0.8991933,0.000244643],"about_ca_topic_score_codex":0.0000032295397,"about_ca_topic_score_gemma":0.000012887961,"teacher_disagreement_score":0.89112824,"about_ca_system_score_codex":0.00045222195,"about_ca_system_score_gemma":0.005506819,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W3178156199","doi":"10.1186/s13045-021-01122-1","title":"Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study","year":2021,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Karyopharm Therapeutics","keywords":"Medicine; Refractory (planetary science); Internal medicine; Regimen; Population; Lymphoma; Surgery; Gastroenterology; Hematology","score_opus":0.017846038838583666,"score_gpt":0.2586539734881255,"score_spread":0.24080793464954187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178156199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9522122,0.0010035326,0.0000047986564,0.044278607,0.00055164663,0.0012741673,0.000030151214,0.00001733796,0.00062752323],"genre_scores_gemma":[0.945201,0.00010570982,0.00017819136,0.053120833,0.0006677479,0.00011167782,0.0002301012,0.000101088845,0.00028366258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99444634,0.0016979025,0.0014345751,0.00060946454,0.001012388,0.00079936034],"domain_scores_gemma":[0.9951076,0.0014353087,0.0018810937,0.00070803054,0.0006922878,0.00017571192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062051846,0.0007161422,0.002843234,0.0005143911,0.00012694299,0.00003781602,0.00040573452,0.0010943324,0.00009176792],"category_scores_gemma":[0.000109881556,0.0003637443,0.00033193297,0.00039423237,0.00025697154,0.00010916192,0.00009011856,0.0016858669,0.000013916288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018588644,0.06805159,0.72659856,0.000105340005,0.0013979544,0.12536912,0.0010462318,8.959785e-7,0.0000028757372,0.0000022849517,0.07524138,0.0003248791],"study_design_scores_gemma":[0.12721814,0.038117103,0.6640449,0.0005944669,0.0041837757,0.008689984,0.0027483918,0.0000021674325,0.00007913281,0.0000031010813,0.15382335,0.0004954986],"about_ca_topic_score_codex":0.00013330749,"about_ca_topic_score_gemma":0.0009914457,"teacher_disagreement_score":0.12535928,"about_ca_system_score_codex":0.0013339109,"about_ca_system_score_gemma":0.001275199,"threshold_uncertainty_score":0.99988145},"labels":[],"label_agreement":null},{"id":"W3197223132","doi":"10.1186/s13045-021-01144-9","title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Oncology; Confidence interval; Surgery","score_opus":0.07529656742620855,"score_gpt":0.4012486531152399,"score_spread":0.32595208568903133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197223132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98579115,0.005235145,0.000026679058,0.001670333,0.0010404453,0.0003212502,0.000008586143,0.000017492057,0.005888932],"genre_scores_gemma":[0.99389845,0.0011507506,0.0015784509,0.00020809757,0.00016364286,0.000014728796,0.000017563323,0.00004907686,0.0029192155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960372,0.00094063167,0.0015818056,0.0003337395,0.00047198572,0.00063467596],"domain_scores_gemma":[0.9956439,0.0021100221,0.0010591652,0.00044500566,0.00046866597,0.0002731985],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091276685,0.00029121846,0.0024750554,0.0006915795,0.00006584482,0.000008023474,0.0002439739,0.00066375616,0.0023151548],"category_scores_gemma":[0.00037938743,0.0002245435,0.000384175,0.0005499016,0.00019583819,0.000067641544,0.00010669979,0.00079466327,0.000036495563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15628749,0.0959655,0.14325686,0.0012558127,0.0040773414,0.08125877,0.02649646,0.000073489595,0.40073836,0.00087125326,0.012128428,0.077590264],"study_design_scores_gemma":[0.24881932,0.062652424,0.022088943,0.00068894017,0.0013815971,0.024240874,0.023450091,0.00030001425,0.395127,0.00026843592,0.22032529,0.0006570682],"about_ca_topic_score_codex":0.00009435361,"about_ca_topic_score_gemma":0.0016414354,"teacher_disagreement_score":0.20819686,"about_ca_system_score_codex":0.0015011893,"about_ca_system_score_gemma":0.0032397672,"threshold_uncertainty_score":0.99859685},"labels":[],"label_agreement":null},{"id":"W3209835908","doi":"10.1186/s13045-021-01202-2","title":"Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":574,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; York University","funders":"Shahid Beheshti University of Medical Sciences; Institute for Health Metrics and Evaluation","keywords":"Burden of disease; Anemia; Medicine; Disease; Environmental health; Hematology; Disease burden; Internal medicine","score_opus":0.02272164618525887,"score_gpt":0.3320074399437873,"score_spread":0.30928579375852844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209835908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9434752,0.04644067,0.000004080405,0.009173132,0.0004235796,0.00022538085,0.00015055134,0.0000033747122,0.00010405436],"genre_scores_gemma":[0.99644125,0.0029170811,0.00016670581,0.00023407496,0.00017079561,0.0000019740933,0.000015543252,0.000008272587,0.0000443176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803364,0.000369713,0.0009294478,0.00020712704,0.00025075537,0.00020932748],"domain_scores_gemma":[0.99780345,0.00091204286,0.00063116685,0.00021218756,0.00029865306,0.0001424837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053478766,0.00015234757,0.0010286816,0.0000864242,0.000051255698,0.000008507856,0.00013064581,0.00017097128,0.000026655676],"category_scores_gemma":[0.0010688666,0.000106650965,0.00006090366,0.00015393608,0.00033092612,0.00009572781,0.000115932446,0.00027850267,8.719356e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010267369,0.0009912278,0.9573995,0.00039595095,0.00042787005,0.0037798092,0.014430882,0.000068048525,0.0013496017,0.003130313,0.0067182393,0.0010412002],"study_design_scores_gemma":[0.029065574,0.0027015219,0.8869827,0.0005455917,0.0020779723,0.0028155555,0.055886276,0.000031613137,0.00060910673,0.0027282499,0.016279578,0.00027630414],"about_ca_topic_score_codex":0.0023701529,"about_ca_topic_score_gemma":0.0013493492,"teacher_disagreement_score":0.07041683,"about_ca_system_score_codex":0.00005742035,"about_ca_system_score_gemma":0.0009969453,"threshold_uncertainty_score":0.43491003},"labels":[],"label_agreement":null},{"id":"W4214875473","doi":"10.1186/s13045-022-01235-1","title":"The long and short non-coding RNAs modulating EZH2 signaling in cancer","year":2022,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Cancer Science Institute of Singapore, National University of Singapore; Ministry of Education, India; Terry Fox Research Institute; National Research Foundation; Ministry of Education - Singapore; National Research Foundation Singapore; National University of Singapore; Cancer Research UK","keywords":"Hematology; EZH2; Internal medicine; Coding (social sciences); Cancer; Medicine; Long non-coding RNA; Cancer research; Oncology; Biology; Computational biology; Bioinformatics; Genetics; RNA; Histone; DNA; Gene; Mathematics","score_opus":0.05187591141921844,"score_gpt":0.40656639184297055,"score_spread":0.3546904804237521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214875473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00057466613,0.9958264,0.001639959,0.00020860288,0.0010345882,0.00047770978,0.000007400604,0.0000032494138,0.00022739402],"genre_scores_gemma":[0.002040836,0.99675226,0.00034536407,0.000085058644,0.00047184486,0.00013337178,0.000018492721,0.00007388308,0.00007885781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964426,0.00084643485,0.0013379076,0.000452554,0.0003096496,0.0006108424],"domain_scores_gemma":[0.99796516,0.00050156895,0.0009287095,0.00033328767,0.00013029661,0.00014097278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020142111,0.0003662826,0.0017359712,0.00035470203,0.0002795228,0.00003498166,0.00065665465,0.0007826314,0.000055604538],"category_scores_gemma":[0.0004095157,0.00027968752,0.0004507255,0.00029583467,0.00020208202,0.0000070402148,0.00058903266,0.0018172207,0.000001280958],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014587282,0.00009354882,0.000035667577,0.0015428014,0.00086522585,0.00140634,0.00007456888,0.000430719,0.0033095751,0.0001862482,0.00067687395,0.9912326],"study_design_scores_gemma":[0.0005442556,0.00080432394,0.0000036761014,0.0014414138,0.00036749875,0.008860356,0.00013112147,0.00007059119,0.0014000521,0.00005176918,0.9860242,0.0003007118],"about_ca_topic_score_codex":0.000026648395,"about_ca_topic_score_gemma":0.00023148135,"teacher_disagreement_score":0.99093187,"about_ca_system_score_codex":0.00043960847,"about_ca_system_score_gemma":0.001809267,"threshold_uncertainty_score":0.99996555},"labels":[],"label_agreement":null},{"id":"W4225292988","doi":"10.1186/s13045-022-01268-6","title":"Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena","year":2022,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Canadian Cancer Society; Foundation for the National Institutes of Health","keywords":"Prostate cancer; Medicine; Prostate; Magnetic resonance imaging; Visibility; Radiology; Cancer; Pathology; Internal medicine","score_opus":0.01817164259771498,"score_gpt":0.31568404235698816,"score_spread":0.2975123997592732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225292988","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06281816,0.2644899,0.000003861509,0.66738075,0.0027464032,0.0015142378,0.00023817283,0.00004151847,0.0007670208],"genre_scores_gemma":[0.030379215,0.016787525,0.0016848373,0.94464296,0.003628815,0.00094794616,0.000087118984,0.00021414977,0.0016274208],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948814,0.00056203123,0.0019216554,0.0008624013,0.00074500474,0.0010275277],"domain_scores_gemma":[0.99509275,0.0010602918,0.0022105312,0.0007133895,0.0006643204,0.00025872886],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007698263,0.00064678566,0.003106941,0.0010726701,0.00017883567,0.000028142691,0.00044915624,0.00046469911,0.0036679131],"category_scores_gemma":[0.0003133577,0.0005294287,0.0006808088,0.0007323521,0.00045345142,0.00012202241,0.00025656447,0.004317291,0.000039512062],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001334874,0.00083753676,0.080125146,0.0005486434,0.00039674042,0.050892867,0.0006144536,0.0000025794152,0.000017417164,0.000017545599,0.79193026,0.073281914],"study_design_scores_gemma":[0.0064310017,0.0051311795,0.009092345,0.00040401198,0.0012602231,0.020134857,0.00013877943,0.000024222145,0.00021171443,0.00035700932,0.9564422,0.00037248945],"about_ca_topic_score_codex":0.00019599154,"about_ca_topic_score_gemma":0.000019782203,"teacher_disagreement_score":0.27726224,"about_ca_system_score_codex":0.0036734357,"about_ca_system_score_gemma":0.0029486925,"threshold_uncertainty_score":0.99971575},"labels":[],"label_agreement":null},{"id":"W4229027500","doi":"10.1186/s13045-022-01276-6","title":"Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer","year":2022,"lang":"en","type":"erratum","venue":"Journal of Hematology & Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hematology; EZH2; Coding (social sciences); Long non-coding RNA; Computational biology; Cancer; Internal medicine; Correct name; Cancer research; Medicine; Bioinformatics; Oncology; Biology; Genetics; RNA; Histone; DNA; Mathematics; Gene; Statistics","score_opus":0.01855452138919512,"score_gpt":0.33637528792193194,"score_spread":0.31782076653273683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229027500","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14221372,0.31831735,0.06476246,0.023045542,0.39810413,0.004970321,0.00013465191,0.00007441652,0.048377406],"genre_scores_gemma":[0.894584,0.04626123,0.0013777296,0.003033679,0.014206363,0.0005003006,0.0003204939,0.00047439837,0.03924178],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969439,0.0005968911,0.0009782641,0.0004976609,0.00040924238,0.00057402847],"domain_scores_gemma":[0.99827546,0.00019885428,0.0007750291,0.00034181157,0.00028008423,0.00012874042],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001466588,0.0003445001,0.0009798149,0.00040406315,0.00027598496,0.00003315505,0.0005802167,0.0011217276,0.00020928544],"category_scores_gemma":[0.00040001355,0.00029414654,0.0002659201,0.0002936971,0.00022584741,0.000009108566,0.0005524989,0.003426614,0.000001163352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008940255,0.00026793312,0.0008990312,0.00026897973,0.0012697316,0.0030989188,0.0005500956,0.011498897,0.12245023,0.00010476206,0.83740956,0.021287825],"study_design_scores_gemma":[0.0029062822,0.0046234545,0.000769239,0.0010254671,0.00059683557,0.0334668,0.0017671906,0.0058244504,0.070169225,0.00020565598,0.8775352,0.0011101683],"about_ca_topic_score_codex":0.00011513084,"about_ca_topic_score_gemma":0.00092822814,"teacher_disagreement_score":0.7523703,"about_ca_system_score_codex":0.0004721872,"about_ca_system_score_gemma":0.0018977987,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W4281263643","doi":"10.1186/s13045-022-01289-1","title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","year":2022,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Internal medicine; Low molecular weight heparin; Relative risk; Heparin; Cancer; Hematology; Major bleeding; Intensive care medicine; Confidence interval","score_opus":0.11199116437394019,"score_gpt":0.4325701751751657,"score_spread":0.32057901080122553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281263643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001326381,0.9782501,0.000032116466,0.001061393,0.00066684705,0.0195096,0.0002593353,0.000010316661,0.000077690136],"genre_scores_gemma":[0.00037865495,0.9932437,0.00011347716,0.00030665356,0.000036137462,0.005651232,0.00013975456,0.00005909582,0.0000712844],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97858375,0.010918535,0.008965401,0.00044749805,0.000642914,0.0004418711],"domain_scores_gemma":[0.95377046,0.025127517,0.019654464,0.000695565,0.00060988916,0.00014210666],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.015870519,0.0007947517,0.14981446,0.0010913756,0.00012526715,0.000013153196,0.00045616302,0.00043388983,0.0011475837],"category_scores_gemma":[0.0059570624,0.00035654687,0.021760866,0.0009086941,0.00032766905,0.00003216566,0.00009412266,0.00036174696,7.2096395e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009928198,0.0036371164,4.8950795e-7,0.14085253,0.84258217,0.00024273152,0.000119671204,0.000013006706,0.0000017925809,0.00054801407,0.0008230966,0.0012512133],"study_design_scores_gemma":[0.092297986,0.003392166,6.5749015e-7,0.006318634,0.8716816,0.00017162229,0.000053622116,0.000034223198,0.000011611573,0.000015023649,0.02582731,0.00019558193],"about_ca_topic_score_codex":0.0001796338,"about_ca_topic_score_gemma":0.00011467537,"teacher_disagreement_score":0.1345339,"about_ca_system_score_codex":0.0006066259,"about_ca_system_score_gemma":0.0011193778,"threshold_uncertainty_score":0.99988866},"labels":[],"label_agreement":null},{"id":"W4293125198","doi":"10.1186/s13045-022-01333-0","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Thrombosis; Hematology; Internal medicine; Chronic lymphocytic leukemia; Retrospective cohort study; Coronavirus disease 2019 (COVID-19); Disease; Intensive care medicine; Pediatrics; Leukemia; Infectious disease (medical specialty)","score_opus":0.08628222026284342,"score_gpt":0.39319395771899157,"score_spread":0.30691173745614814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293125198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950027,0.0005474704,0.000009130732,0.0016982019,0.000054909964,0.0010438877,0.000004383708,0.000006557732,0.0016327751],"genre_scores_gemma":[0.99913466,0.00009154099,0.00008030467,0.0005671429,0.000037870454,0.000043475397,0.0000029025327,0.000024322864,0.000017807131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953949,0.0024990023,0.00070252107,0.00029070245,0.0007121837,0.00040068058],"domain_scores_gemma":[0.99553967,0.0030869278,0.00047886837,0.00030941633,0.00035843338,0.00022670365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033134248,0.0001468656,0.0007489211,0.000605226,0.00038078876,0.000010211772,0.0003017767,0.00006727312,0.000058515714],"category_scores_gemma":[0.0008684561,0.000097469194,0.000036775862,0.00062515226,0.00081823923,0.000064134176,0.00046450133,0.0011750745,0.0000028391999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024935875,0.009300026,0.8234851,0.0019284554,0.0031036523,0.012788381,0.08768068,0.014281699,0.0005445097,0.007390873,0.0092721265,0.0052886433],"study_design_scores_gemma":[0.18425159,0.098654434,0.6311866,0.00046473995,0.0004842848,0.030453896,0.046779886,0.0038973396,0.000044730565,0.0009577905,0.002479888,0.00034480888],"about_ca_topic_score_codex":0.00031259685,"about_ca_topic_score_gemma":0.00026393,"teacher_disagreement_score":0.19229847,"about_ca_system_score_codex":0.04520784,"about_ca_system_score_gemma":0.024507584,"threshold_uncertainty_score":0.98102254},"labels":[],"label_agreement":null},{"id":"W4323311378","doi":"10.1186/s13045-023-01417-5","title":"Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Gilead Sciences","keywords":"Meta-analysis; Hematology; Myeloid leukemia; Medicine; Internal medicine; Oncology; Hematologic Neoplasms; Intensive care medicine; Cancer","score_opus":0.13974557173687224,"score_gpt":0.455098530342097,"score_spread":0.3153529586052248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323311378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026291136,0.9825588,0.00008717863,0.006088064,0.00018659933,0.010527849,0.00037884092,0.00007054006,0.00007586051],"genre_scores_gemma":[0.0000049230225,0.9857608,0.0020629375,0.0009441342,0.00011322551,0.0044252286,0.00028312558,0.00019927295,0.0062063634],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9896147,0.0021587762,0.005553252,0.0009871265,0.0005775135,0.0011086334],"domain_scores_gemma":[0.9809895,0.010586604,0.005591576,0.0012343863,0.0008611681,0.0007367259],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0019411315,0.0015415283,0.05042225,0.0024795828,0.000187591,0.000044005625,0.0006350285,0.0015405001,0.00021509199],"category_scores_gemma":[0.0020332446,0.0007932673,0.012995213,0.0016755739,0.00036345643,0.0001290202,0.00017464376,0.0010911194,0.00016342243],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010493428,0.0003810651,0.000012216557,0.34358582,0.63699174,0.011907873,0.00010088321,7.0213576e-7,2.4648142e-7,0.00009372774,0.0024406703,0.0043800925],"study_design_scores_gemma":[0.0041117184,0.00545615,0.0000018489363,0.009949524,0.8205922,0.03871297,0.000088420566,0.000008697504,0.0000015996343,0.000031992862,0.12067009,0.00037475638],"about_ca_topic_score_codex":0.00009656154,"about_ca_topic_score_gemma":0.00015640144,"teacher_disagreement_score":0.3336363,"about_ca_system_score_codex":0.007799149,"about_ca_system_score_gemma":0.0069155223,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W4364381091","doi":"10.1186/s13045-023-01431-7","title":"Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study","year":2023,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; TG Therapeutics; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Medical College of Wisconsin; StemCyte; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Incyte; Pfizer; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; CSL Behring; AstraZeneca; Bristol-Myers Squibb; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; Jazz Pharmaceuticals; Be The Match Foundation","keywords":"Hematopoietic cell; Hematology; Myelodysplastic syndromes; Medicine; Internal medicine; Oncology; Hematologic Neoplasms; Haematopoiesis; Genetics; Biology; Stem cell; Transplantation; Bone marrow","score_opus":0.029290541222779326,"score_gpt":0.30702762840655023,"score_spread":0.2777370871837709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364381091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84977764,0.00026090804,0.0038740146,0.13414752,0.0027249486,0.0078858975,0.0011802765,0.000100452344,0.00004834944],"genre_scores_gemma":[0.876873,0.00014641724,0.010393994,0.091942415,0.0035887905,0.0031878469,0.0040179333,0.0014055028,0.008444089],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99373215,0.00028599447,0.002472916,0.00087170536,0.0011670479,0.0014702],"domain_scores_gemma":[0.9896888,0.005768846,0.0020972795,0.0006485961,0.001462487,0.0003339566],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013829493,0.0008768701,0.0046118805,0.0017409568,0.00026037992,0.00004844622,0.0008708102,0.0017383103,0.000055317505],"category_scores_gemma":[0.00073325535,0.0006233756,0.00082736544,0.00042025183,0.00045440768,0.00017330873,0.00013310384,0.003493989,0.000034493103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010265842,0.005811684,0.14996582,0.018167887,0.016737994,0.06560723,0.009472332,0.000112256195,0.0021069038,0.0000340228,0.7216648,0.00005323656],"study_design_scores_gemma":[0.19755584,0.19218002,0.0954051,0.006006471,0.039801877,0.13363498,0.011361129,0.00024339513,0.00044634883,0.0006885842,0.31838244,0.00429379],"about_ca_topic_score_codex":0.000015422374,"about_ca_topic_score_gemma":0.000042620624,"teacher_disagreement_score":0.40328234,"about_ca_system_score_codex":0.0019310584,"about_ca_system_score_gemma":0.0036792755,"threshold_uncertainty_score":0.99962175},"labels":[],"label_agreement":null},{"id":"W4389831827","doi":"10.1186/s13045-023-01520-7","title":"Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary","funders":"National Cancer Institute","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Oncology; Cohort; Retrospective cohort study; Hematology; Hematopoietic stem cell transplantation; Transplantation; Lymphoma","score_opus":0.032297133307245776,"score_gpt":0.3348060902558893,"score_spread":0.30250895694864355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389831827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973244,0.0023847502,0.00039342727,0.005997925,0.00022086407,0.0007401526,0.000092969516,0.000016415617,0.0004210647],"genre_scores_gemma":[0.99342656,0.0012641037,0.0032067439,0.0016420645,0.000087038876,0.00017021655,0.00011173581,0.000022857861,0.0000687048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700636,0.00039239792,0.0014909899,0.0003825815,0.00031021822,0.00041744727],"domain_scores_gemma":[0.9911431,0.006029686,0.0018651027,0.00048505477,0.00039274877,0.0000842722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009989792,0.00031145223,0.0020408926,0.00040842535,0.000106300206,0.000015549387,0.00040924703,0.00022180068,0.00001555233],"category_scores_gemma":[0.0004974997,0.00015101787,0.000793229,0.0011695212,0.0005842411,0.000055315722,0.00006975946,0.00022767007,0.000004869758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030040988,0.009704208,0.9580492,0.000048035992,0.0023781867,0.006888155,0.00402172,0.00023114202,0.00081500347,0.00049845874,0.0071511446,0.0072106565],"study_design_scores_gemma":[0.010380259,0.0031289642,0.96854264,0.000060919698,0.0035899198,0.00478412,0.004754226,0.00087361946,0.0020422265,0.00048491123,0.0012001507,0.0001580448],"about_ca_topic_score_codex":0.00037593197,"about_ca_topic_score_gemma":0.0010736883,"teacher_disagreement_score":0.010493449,"about_ca_system_score_codex":0.00020670365,"about_ca_system_score_gemma":0.00072411995,"threshold_uncertainty_score":0.615833},"labels":[],"label_agreement":null},{"id":"W4393397203","doi":"10.1186/s13045-024-01535-8","title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Nanoplatforms for cancer theranostics","field":"Engineering","cited_by":333,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"National University Health System; National Natural Science Foundation of China","keywords":"Tumor microenvironment; Immunotherapy; Immune system; Cancer immunotherapy; Cancer research; Medicine; Nanocarriers; Cancer cell; Cancer; Immunology; Pharmacology; Internal medicine","score_opus":0.010035341975949318,"score_gpt":0.26504064326531873,"score_spread":0.25500530128936943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393397203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8973077,0.10034181,0.00065857207,0.0005717614,0.00095885893,0.000066685796,0.0000017737395,0.00004198218,0.000050846527],"genre_scores_gemma":[0.98804146,0.009742534,0.0019087723,0.00016912611,0.00007761862,0.000007666936,1.768167e-7,0.00004327181,0.000009377404],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990567,0.000024973819,0.00051338784,0.00009510698,0.00007489788,0.00023494622],"domain_scores_gemma":[0.9996452,0.00014881285,0.0000665567,0.00007393435,0.000014979116,0.00005056894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025265568,0.00012031354,0.00040336463,0.00019816987,0.000015241206,0.000013652329,0.00009851789,0.00009905716,0.000037996993],"category_scores_gemma":[0.000009292106,0.00010211456,0.000055690853,0.00009705071,0.00007587972,0.00012961226,0.000017094779,0.00033204706,0.000004840103],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012914256,0.000048231246,0.002776322,0.00015746264,0.00018328399,0.0011136957,0.0011825468,0.007816685,0.9187519,0.0005061645,0.00053453934,0.06680001],"study_design_scores_gemma":[0.005624535,0.0013859068,0.002731587,0.0013832503,0.00023516861,0.023008823,0.00096930494,0.050579693,0.44964746,0.012086406,0.4515402,0.00080767967],"about_ca_topic_score_codex":0.000008574894,"about_ca_topic_score_gemma":0.000044334865,"teacher_disagreement_score":0.46910447,"about_ca_system_score_codex":0.0003390268,"about_ca_system_score_gemma":0.00008876227,"threshold_uncertainty_score":0.4164111},"labels":[],"label_agreement":null},{"id":"W4395007321","doi":"10.1186/s13045-024-01542-9","title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","year":2024,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Incyte; TG Therapeutics; National Cancer Institute; Laffey-McHugh Foundation; Pharmacyclics; Genentech; Celgene; Mallinckrodt Pharmaceuticals; Society for Immunotherapy of Cancer; University of Pennsylvania; Gilead Sciences; Leukemia and Lymphoma Society","keywords":"Bendamustine; Medicine; Cytokine release syndrome; Internal medicine; Fludarabine; Cyclophosphamide; Gastroenterology; Lymphoma; Immunotherapy; Rituximab; Chemotherapy; Cancer; Chimeric antigen receptor","score_opus":0.03244576333228277,"score_gpt":0.3624544389628308,"score_spread":0.33000867563054803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395007321","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09233999,0.011098578,0.00041293548,0.89095455,0.0020776133,0.0015514443,0.0001049317,0.000031685573,0.0014282621],"genre_scores_gemma":[0.07211879,0.015371605,0.037809227,0.7506124,0.045480557,0.00035576266,0.0016034822,0.0013895866,0.075258635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966465,0.00028991973,0.0016284252,0.00040214317,0.00046389014,0.0005691197],"domain_scores_gemma":[0.996044,0.0016160832,0.0011130009,0.00035810727,0.0007051632,0.00016366149],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012929197,0.00037677094,0.0026288144,0.0009291803,0.000059968155,0.000011652863,0.00027433303,0.0019605893,0.00094414304],"category_scores_gemma":[0.0005271291,0.00029567262,0.0005908001,0.00021817967,0.000543031,0.000047811234,0.00013665514,0.0024355855,0.000012573841],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008101726,0.00031252252,0.00080737873,0.0038660287,0.0020802333,0.00675065,0.0003760271,0.0000016681847,0.006693119,0.00024406002,0.9442529,0.026513677],"study_design_scores_gemma":[0.0085519515,0.007830099,0.00077977375,0.00071604794,0.0014013995,0.043488663,0.00005013025,0.000043685857,0.0010185706,0.0006618524,0.9352888,0.00016904861],"about_ca_topic_score_codex":0.000010284876,"about_ca_topic_score_gemma":0.000018286933,"teacher_disagreement_score":0.1403422,"about_ca_system_score_codex":0.00050692796,"about_ca_system_score_gemma":0.0013088466,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W4396904518","doi":"10.1186/s13045-024-01541-w","title":"Critical role of the gut microbiota in immune responses and cancer immunotherapy","year":2024,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"National Natural Science Foundation of China; National Science Foundation","keywords":"Hematology; Immunotherapy; Immune system; Cancer; Cancer immunotherapy; Medicine; Gut flora; Immunology; Internal medicine; Oncology","score_opus":0.020512318260275622,"score_gpt":0.40514961243919795,"score_spread":0.38463729417892234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396904518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011316637,0.98640054,0.0000016851027,0.0010902476,0.00084587594,0.00024379404,0.000039132727,0.0000025115705,0.000059575694],"genre_scores_gemma":[0.0031245747,0.99611545,0.00020825746,0.00020148676,0.000153879,0.000014566361,0.0000041376697,0.000050828134,0.00012682358],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972332,0.00076855405,0.0013409038,0.00026980654,0.000069362475,0.00031816153],"domain_scores_gemma":[0.9984894,0.00023571038,0.0007618479,0.0003131763,0.00014225581,0.000057603673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006862407,0.00028922103,0.0019875965,0.0002458698,0.000039614475,0.000010069713,0.0004503093,0.00095862884,0.000021726255],"category_scores_gemma":[0.0002065927,0.00017951237,0.0005208127,0.00016598227,0.00050453097,0.000003608611,0.00022957064,0.0008541328,0.000002545291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096716004,0.00067223696,0.00052280386,0.016144255,0.0016342188,0.0003260301,0.0004833341,5.0894937e-7,0.55817443,0.0023787234,0.008082653,0.41061366],"study_design_scores_gemma":[0.00041950244,0.0005307806,0.0001938902,0.0035709047,0.00043296866,0.009064079,0.00006613622,1.4972194e-7,0.0010102798,0.00013016885,0.98443246,0.00014868763],"about_ca_topic_score_codex":0.0000343185,"about_ca_topic_score_gemma":0.00009588143,"teacher_disagreement_score":0.9763498,"about_ca_system_score_codex":0.00010165772,"about_ca_system_score_gemma":0.0022357325,"threshold_uncertainty_score":0.7393823},"labels":[],"label_agreement":null},{"id":"W4399775192","doi":"10.1186/s13045-024-01565-2","title":"Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study","year":2024,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Prospective cohort study; Esophageal cancer; Multiplex; Cell-free fetal DNA; Cancer; Receiver operating characteristic; Stage (stratigraphy); Oncology; Bioinformatics; Prenatal diagnosis; Biology","score_opus":0.03270343736734796,"score_gpt":0.36867562552479805,"score_spread":0.3359721881574501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399775192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7801678,0.065499924,0.000071098875,0.14753571,0.0012169569,0.0048980056,0.00015212108,0.000037388818,0.0004209649],"genre_scores_gemma":[0.98470855,0.0011367586,0.0006721906,0.011103888,0.001374692,0.0006855277,0.00005242572,0.00010510473,0.00016084642],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954183,0.0005675259,0.001726155,0.0007078514,0.00085556,0.0007245875],"domain_scores_gemma":[0.9943809,0.002059751,0.0019966012,0.00039135243,0.0009105653,0.00026085693],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012586141,0.0005639493,0.0026390282,0.0007447994,0.00013588199,0.00003631784,0.0003374511,0.0010094995,0.00013404118],"category_scores_gemma":[0.00054099166,0.0004398366,0.00042522003,0.00034967877,0.000290566,0.00014414327,0.00028603213,0.0033779177,0.0000071363065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054039275,0.0033518048,0.4925391,0.004485307,0.007590022,0.05800995,0.0050162063,0.00001654276,0.0015358742,0.00002061636,0.4202765,0.0017541279],"study_design_scores_gemma":[0.39459804,0.103824645,0.058746908,0.011180059,0.04516657,0.025169859,0.014554796,0.00065028213,0.30031353,0.0037510747,0.038090225,0.003954015],"about_ca_topic_score_codex":0.00042920787,"about_ca_topic_score_gemma":0.00018531232,"teacher_disagreement_score":0.4337922,"about_ca_system_score_codex":0.001254163,"about_ca_system_score_gemma":0.0016157767,"threshold_uncertainty_score":0.99980533},"labels":[],"label_agreement":null},{"id":"W4405659313","doi":"10.1186/s13045-024-01653-3","title":"Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study","year":2024,"lang":"en","type":"erratum","venue":"Journal of Hematology & Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Hematology; Esophageal cancer; Medicine; Internal medicine; Oncology; DNA methylation; Double blinded; Multicenter study; Methylation; Prospective cohort study; Cancer; Pathology; Cancer research; DNA; Biology; Randomized controlled trial; Alternative medicine; Biochemistry; Gene","score_opus":0.0269657228408138,"score_gpt":0.3683365384295238,"score_spread":0.34137081558871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405659313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65074855,0.28436804,0.00025805147,0.005539659,0.042556982,0.009495317,0.0002479169,0.00009682283,0.0066886568],"genre_scores_gemma":[0.990078,0.0038042255,0.0003877969,0.00013284745,0.0014720347,0.0006621726,0.000062254454,0.00009993256,0.003300791],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955376,0.0005628715,0.0017440116,0.0007128593,0.00081957114,0.0006230804],"domain_scores_gemma":[0.994175,0.0016804276,0.0022134464,0.00036816156,0.0011871321,0.00037583473],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013631785,0.0005639359,0.0026747545,0.00076066086,0.00018331147,0.00003884405,0.00029518304,0.000892336,0.00016430045],"category_scores_gemma":[0.000993944,0.00045334085,0.0004214714,0.00046281776,0.00027730828,0.0001568709,0.00028137854,0.0029790197,0.00000647499],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007668059,0.00522645,0.29272988,0.0030544442,0.006484534,0.0139477635,0.0054393485,0.000028359647,0.0006967135,0.000025817091,0.66108996,0.0036086494],"study_design_scores_gemma":[0.36843866,0.14620909,0.11578416,0.020511983,0.050401557,0.030930635,0.04101187,0.0031855311,0.18254405,0.0022834484,0.034385115,0.004313884],"about_ca_topic_score_codex":0.00059227634,"about_ca_topic_score_gemma":0.0007668902,"teacher_disagreement_score":0.6267049,"about_ca_system_score_codex":0.0016004209,"about_ca_system_score_gemma":0.0029127887,"threshold_uncertainty_score":0.99979186},"labels":[],"label_agreement":null},{"id":"W4406470071","doi":"10.1186/s13045-024-01657-z","title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Foghorn Therapeutics; Celgene; Jazz Pharmaceuticals; Leukemia and Lymphoma Society; GlaxoSmithKline; Servier; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Refractory (planetary science); Open label; Myeloid leukemia; Azacitidine; Hematology; Internal medicine; Clinical trial","score_opus":0.046883493649556594,"score_gpt":0.38586445423521454,"score_spread":0.33898096058565796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406470071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989263,0.00016397783,0.00009829929,0.00670851,0.00026839616,0.0024761525,0.0000140294005,0.000018121325,0.0009895407],"genre_scores_gemma":[0.99120677,0.00020157083,0.0066646105,0.00090125884,0.000050460596,0.0001262694,0.00005885852,0.000044731853,0.00074548443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957554,0.0007740812,0.0017258321,0.00048947975,0.0005614343,0.00069378555],"domain_scores_gemma":[0.9959803,0.0014066236,0.0010645232,0.00043427007,0.0008235627,0.0002906768],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001531726,0.0003579203,0.0021870446,0.0015707879,0.00014888824,0.0000307332,0.0006172684,0.00063918956,0.00009656775],"category_scores_gemma":[0.0014675356,0.00023405334,0.00006673762,0.0012963946,0.00042913965,0.0004941925,0.00023595217,0.0024698253,0.000007808353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8699432,0.019768463,0.065633334,0.00023640438,0.0014808511,0.01606828,0.0008000924,0.00003945975,0.01080109,0.000563269,0.009615859,0.0050496897],"study_design_scores_gemma":[0.8978836,0.056402203,0.029192103,0.001782762,0.0007015934,0.003804269,0.00076031353,0.00042809392,0.0029676766,0.00021257288,0.0054855775,0.00037923214],"about_ca_topic_score_codex":0.00017715193,"about_ca_topic_score_gemma":0.0005412014,"teacher_disagreement_score":0.03663374,"about_ca_system_score_codex":0.0035900755,"about_ca_system_score_gemma":0.008303762,"threshold_uncertainty_score":0.9998315},"labels":[],"label_agreement":null},{"id":"W4406591519","doi":"10.1186/s13045-024-01645-3","title":"Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute; National Institutes of Health; California Institute for Regenerative Medicine","keywords":"Oncolytic virus; Immune system; Flow cytometry; Ex vivo; Cancer research; Cytotoxic T cell; Biology; Proteasome inhibitor; Bortezomib; In vivo; Immunology; Multiple myeloma; Medicine; In vitro","score_opus":0.01607445195790872,"score_gpt":0.3285177114576243,"score_spread":0.3124432594997156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406591519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881615,0.009224607,0.00009770341,0.00055346254,0.00034327392,0.0007883198,0.000004381077,0.000006515844,0.0008202222],"genre_scores_gemma":[0.996693,0.0022685793,0.00024267932,0.0003969106,0.00010591084,0.0000932675,0.0000058901232,0.000022038514,0.0001716991],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971174,0.00096530176,0.00091535854,0.00032563487,0.00025706892,0.00041922272],"domain_scores_gemma":[0.99821955,0.00039174955,0.00066009467,0.00029300706,0.00034445568,0.00009115413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013038946,0.00022970798,0.000883221,0.0005713511,0.00006316744,0.000008997824,0.00037505655,0.0005502533,0.000029887102],"category_scores_gemma":[0.00073550525,0.00020105817,0.00021939886,0.00038122735,0.00024088683,0.000016791233,0.00011323041,0.00048572174,0.0000079450065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008992212,0.0007185178,0.007083545,0.00014578547,0.00025733944,0.00024760302,0.000104946506,0.00004836466,0.9717915,0.00006754476,0.0003305391,0.010212105],"study_design_scores_gemma":[0.005245473,0.012646902,0.0033496795,0.00018786325,0.000022287044,0.00031245922,0.00006854899,0.00002130428,0.97569835,0.00026288413,0.0020413562,0.00014291964],"about_ca_topic_score_codex":0.000009907049,"about_ca_topic_score_gemma":0.0004657344,"teacher_disagreement_score":0.011928385,"about_ca_system_score_codex":0.00015799898,"about_ca_system_score_gemma":0.0011125159,"threshold_uncertainty_score":0.8198914},"labels":[],"label_agreement":null},{"id":"W4415516512","doi":"10.1186/s13045-025-01741-y","title":"B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia","year":2025,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"National Cancer Institute; National Institutes of Health; Center for Cancer Research","keywords":"Chimeric antigen receptor; Immunotherapy; Myeloid leukemia; Antigen; Leukemia; B cell; Myeloid; Flow cytometry","score_opus":0.02319117376752284,"score_gpt":0.3493004129627951,"score_spread":0.3261092391952723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415516512","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02999666,0.0084291855,0.00873268,0.9414389,0.0034081652,0.0024837388,0.00031382957,0.00003356283,0.0051632756],"genre_scores_gemma":[0.0028181605,0.012194153,0.072738566,0.8387432,0.0071224812,0.00017521631,0.0006147853,0.00032749993,0.06526593],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963265,0.00024421036,0.0018248458,0.00039356836,0.00054927386,0.0006616093],"domain_scores_gemma":[0.9947186,0.0011862479,0.002096537,0.0005540738,0.0013471987,0.000097332086],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00094022613,0.00043584305,0.0030054238,0.0011205714,0.00007970949,0.000014771337,0.0005833894,0.0025430217,0.0018128712],"category_scores_gemma":[0.00010635136,0.00036084736,0.0010553737,0.00029609245,0.00033728758,0.00008588184,0.00007974268,0.003193668,0.000011844825],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005039026,0.00024427814,0.00017304522,0.0007914389,0.002685541,0.00094082643,0.00034550444,0.0000013889978,0.19863671,0.000039143335,0.7894746,0.0016284764],"study_design_scores_gemma":[0.00779278,0.0044855364,0.00010565415,0.00026544605,0.00064894825,0.007375201,0.00005553281,0.00004260756,0.07663176,0.00041304738,0.90197796,0.00020554177],"about_ca_topic_score_codex":0.00002282525,"about_ca_topic_score_gemma":0.0000023748667,"teacher_disagreement_score":0.12200494,"about_ca_system_score_codex":0.0009667583,"about_ca_system_score_gemma":0.0049489015,"threshold_uncertainty_score":0.99988437},"labels":[],"label_agreement":null},{"id":"W4416211821","doi":"10.1186/s13045-025-01751-w","title":"Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Hematology; Cohort; IDH1; Myeloid; Mutation; Cohort study","score_opus":0.027824730235924865,"score_gpt":0.3782625102164903,"score_spread":0.35043777998056547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416211821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9433156,0.0011800252,0.0014427688,0.049061354,0.00096393266,0.0011639951,0.00026544748,0.000041145675,0.0025656968],"genre_scores_gemma":[0.97743094,0.00090640696,0.010311921,0.0061179595,0.0010607085,0.00010461257,0.00025036378,0.00006623276,0.0037508502],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609494,0.0004902915,0.0017216889,0.00048346524,0.00043946717,0.0007701589],"domain_scores_gemma":[0.9921944,0.004991271,0.00093476294,0.0005860874,0.0010174414,0.00027604852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019561225,0.00033549638,0.001723681,0.00042356542,0.00028020376,0.000027306509,0.0007138941,0.00074111565,0.00014247154],"category_scores_gemma":[0.0034841446,0.00022658048,0.0004983757,0.00048850226,0.00070083165,0.00014470733,0.00022116827,0.0019683018,0.00006244364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07137945,0.0012334362,0.010164407,0.00010827955,0.0073964666,0.012261873,0.0011822697,0.00007039596,0.026370369,0.0031976504,0.85651857,0.0101168435],"study_design_scores_gemma":[0.2613925,0.023158852,0.03374397,0.0010783724,0.010543895,0.06448392,0.0046412367,0.004104834,0.068538606,0.009734811,0.5175862,0.0009927946],"about_ca_topic_score_codex":0.00017139353,"about_ca_topic_score_gemma":0.00009651098,"teacher_disagreement_score":0.33893237,"about_ca_system_score_codex":0.001776425,"about_ca_system_score_gemma":0.0064937514,"threshold_uncertainty_score":0.99913853},"labels":[],"label_agreement":null}]}